OA20182A - A process for the preparation of a modified release multiple unit oral dosage form of doxylamine succinate and pyridoxine hydrochloride. - Google Patents
A process for the preparation of a modified release multiple unit oral dosage form of doxylamine succinate and pyridoxine hydrochloride. Download PDFInfo
- Publication number
- OA20182A OA20182A OA1202100132 OA20182A OA 20182 A OA20182 A OA 20182A OA 1202100132 OA1202100132 OA 1202100132 OA 20182 A OA20182 A OA 20182A
- Authority
- OA
- OAPI
- Prior art keywords
- mixture
- agents
- weight
- modified release
- coating agents
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 144
- 239000006186 oral dosage form Substances 0.000 title claims abstract description 21
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 title claims description 44
- 229960004172 pyridoxine hydrochloride Drugs 0.000 title claims description 43
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 title claims description 43
- 239000011764 pyridoxine hydrochloride Substances 0.000 title claims description 43
- 238000002360 preparation method Methods 0.000 title abstract 2
- KBAUFVUYFNWQFM-UHFFFAOYSA-N Doxylamine succinate Chemical compound OC(=O)CCC(O)=O.C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 KBAUFVUYFNWQFM-UHFFFAOYSA-N 0.000 title description 34
- 229960005008 doxylamine succinate Drugs 0.000 title description 34
- 239000011248 coating agent Substances 0.000 claims abstract description 239
- 239000000203 mixture Substances 0.000 claims abstract description 223
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 182
- 239000008188 pellet Substances 0.000 claims abstract description 167
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 146
- 238000000576 coating method Methods 0.000 claims abstract description 84
- 239000002702 enteric coating Substances 0.000 claims abstract description 77
- 238000009505 enteric coating Methods 0.000 claims abstract description 77
- 235000008160 pyridoxine Nutrition 0.000 claims abstract description 73
- 239000011677 pyridoxine Substances 0.000 claims abstract description 73
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 72
- HCFDWZZGGLSKEP-UHFFFAOYSA-N doxylamine Chemical compound C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 HCFDWZZGGLSKEP-UHFFFAOYSA-N 0.000 claims abstract description 65
- 229960005178 doxylamine Drugs 0.000 claims abstract description 64
- 239000011247 coating layer Substances 0.000 claims abstract description 62
- 238000005507 spraying Methods 0.000 claims abstract description 43
- 239000000843 powder Substances 0.000 claims abstract description 42
- 239000010410 layer Substances 0.000 claims abstract description 26
- 239000007787 solid Substances 0.000 claims description 80
- 239000007921 spray Substances 0.000 claims description 76
- 239000002245 particle Substances 0.000 claims description 31
- 229920001800 Shellac Polymers 0.000 claims description 26
- 239000004208 shellac Substances 0.000 claims description 26
- 229940113147 shellac Drugs 0.000 claims description 26
- 235000013874 shellac Nutrition 0.000 claims description 26
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims description 26
- 238000004090 dissolution Methods 0.000 claims description 22
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 22
- 239000002904 solvent Substances 0.000 claims description 22
- 239000000454 talc Substances 0.000 claims description 19
- 229910052623 talc Inorganic materials 0.000 claims description 19
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 17
- 239000002775 capsule Substances 0.000 claims description 16
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 13
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 13
- 235000000346 sugar Nutrition 0.000 claims description 13
- -1 methyl méthacrylate Chemical compound 0.000 claims description 11
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 10
- 239000008351 acetate buffer Substances 0.000 claims description 9
- 239000008363 phosphate buffer Substances 0.000 claims description 9
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 8
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 8
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 8
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 7
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 7
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 7
- 239000011148 porous material Substances 0.000 claims description 7
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 239000007902 hard capsule Substances 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- 229940081735 acetylcellulose Drugs 0.000 claims description 4
- 229920002301 cellulose acetate Polymers 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- 239000001103 potassium chloride Substances 0.000 claims description 4
- 235000011164 potassium chloride Nutrition 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 3
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 3
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 3
- 125000005591 trimellitate group Chemical group 0.000 claims description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims 1
- 229960003943 hypromellose Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 abstract description 7
- 239000002552 dosage form Substances 0.000 description 37
- 239000000243 solution Substances 0.000 description 33
- 239000002609 medium Substances 0.000 description 30
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 27
- 229920001577 copolymer Polymers 0.000 description 19
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 18
- 239000003960 organic solvent Substances 0.000 description 17
- 229920003136 Eudragit® L polymer Polymers 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 239000012071 phase Substances 0.000 description 14
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 11
- 239000000463 material Substances 0.000 description 10
- 229920000642 polymer Polymers 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 125000005395 methacrylic acid group Chemical group 0.000 description 9
- 229920002472 Starch Polymers 0.000 description 8
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 8
- 239000008107 starch Substances 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- 229940032147 starch Drugs 0.000 description 8
- 239000002202 Polyethylene glycol Substances 0.000 description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
- 229930006000 Sucrose Natural products 0.000 description 7
- 239000003937 drug carrier Substances 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 239000000377 silicon dioxide Substances 0.000 description 7
- 229960004793 sucrose Drugs 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 235000002639 sodium chloride Nutrition 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 235000012239 silicon dioxide Nutrition 0.000 description 5
- 239000004408 titanium dioxide Substances 0.000 description 5
- 235000010215 titanium dioxide Nutrition 0.000 description 5
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
- 229910002012 Aerosil® Inorganic materials 0.000 description 4
- 239000005995 Aluminium silicate Substances 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- 235000012211 aluminium silicate Nutrition 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000012738 dissolution medium Substances 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 238000007873 sieving Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229920003134 Eudragit® polymer Polymers 0.000 description 3
- 229920002907 Guar gum Polymers 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
- 229920003081 Povidone K 30 Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000665 guar gum Substances 0.000 description 3
- 235000010417 guar gum Nutrition 0.000 description 3
- 229960002154 guar gum Drugs 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- 229940069328 povidone Drugs 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- 229910002024 Aerosil® 200 Pharma Inorganic materials 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 229920003139 Eudragit® L 100 Polymers 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 2
- 229920002494 Zein Polymers 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- PZZYQPZGQPZBDN-UHFFFAOYSA-N aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 2
- 229910000323 aluminium silicate Inorganic materials 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 238000004630 atomic force microscopy Methods 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 229920006237 degradable polymer Polymers 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- 238000013265 extended release Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229920001903 high density polyethylene Polymers 0.000 description 2
- 239000004700 high-density polyethylene Substances 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 239000002050 international nonproprietary name Substances 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical group CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- 239000004172 quinoline yellow Substances 0.000 description 2
- 235000012752 quinoline yellow Nutrition 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000001069 triethyl citrate Substances 0.000 description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 2
- 235000013769 triethyl citrate Nutrition 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000005019 zein Substances 0.000 description 2
- 229940093612 zein Drugs 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000004031 Carboxy-Lyases Human genes 0.000 description 1
- 108090000489 Carboxy-Lyases Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920003143 Eudragit® FS 30 D Polymers 0.000 description 1
- 229920003135 Eudragit® L 100-55 Polymers 0.000 description 1
- 229920003138 Eudragit® L 30 D-55 Polymers 0.000 description 1
- 229920003142 Eudragit® S 12,5 Polymers 0.000 description 1
- 229920003137 Eudragit® S polymer Polymers 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 102000003834 Histamine H1 Receptors Human genes 0.000 description 1
- 108090000110 Histamine H1 Receptors Proteins 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- LUJQXGBDWAGQHS-UHFFFAOYSA-N ethenyl acetate;phthalic acid Chemical compound CC(=O)OC=C.OC(=O)C1=CC=CC=C1C(O)=O LUJQXGBDWAGQHS-UHFFFAOYSA-N 0.000 description 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
- 239000004179 indigotine Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- DCUFMVPCXCSVNP-UHFFFAOYSA-N methacrylic anhydride Chemical compound CC(=C)C(=O)OC(=O)C(C)=C DCUFMVPCXCSVNP-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- IQSHMXAZFHORGY-UHFFFAOYSA-N methyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound COC(=O)C=C.CC(=C)C(O)=O IQSHMXAZFHORGY-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000008185 minitablet Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N n-hexadecyl alcohol Natural products CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- 229940051201 quinoline yellow Drugs 0.000 description 1
- IZMJMCDDWKSTTK-UHFFFAOYSA-N quinoline yellow Chemical compound C1=CC=CC2=NC(C3C(C4=CC=CC=C4C3=O)=O)=CC=C21 IZMJMCDDWKSTTK-UHFFFAOYSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- QWSZRRAAFHGKCH-UHFFFAOYSA-M sodium;hexane-1-sulfonate Chemical compound [Na+].CCCCCCS([O-])(=O)=O QWSZRRAAFHGKCH-UHFFFAOYSA-M 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 229920006163 vinyl copolymer Polymers 0.000 description 1
- 229920003176 water-insoluble polymer Polymers 0.000 description 1
Abstract
The present invention relates to a process for the preparation of a modified release multiple unit oral dosage form comprising a plurality of modified release pellets of doxylamine or salt thereof and a modified release pellets of pyridoxine or a salt thereof; wherein the process comprises coating the pellets of doxylamine having the inner active coating layer and the intermediate enteric coating layer; and the pellets of pyridoxine having the inner active coating layer, wherein the coating step comprising simultaneous spraying of a mixture comprising the enteric and modified release coating agents and a adding pore-forming agents in powder form.
Description
A process for the préparation of a modified release multiple unit oral dosage form of doxylamine succinate and pyridoxine hydrochloride
The présent invention reïates to a process for the préparation of a modified reiease muitipie unit oral dosage form of modified release pellets of doxylamine or a pharmaceutically acceptable sait thereof and modified release pellets of pyridoxine or a pharmaceutically acceptable sait thereof.
Background Art
Doxylamine is the International Nonproprietary Name of (RS)-/V,/V-dimethyl-2-(1 -phenyl-1pyridin-2-yl-ethoxyj-ethanaminë having the CAS number 469-21-6. Doxylamine is the firstgeneration of antihistamine that competitively, reversibly and non-specifically blocks H1 receptors and is also a non-specific antagonist that can block other receptors such as central or peripheral muscarinic receptors, with marked anticholinergic activity. It is commonly used in form of a sait and particularly in form of its succinate sait. The structure of doxylamine corresponds to the formula (I):
On the other hand, pyridoxine also known as vitamin Beis the International Nonproprietary Name of 4,5-Bis(hydroxymethyl)-2-methylpyridin-3-ol having the CAS number 65-23-6. Pyridoxine is a water-soîuble vitamin factor whose active form is pyridoxal phosphate, it acts as an enzyme co-factor in numerous biochemical reactions involved in the digestive breakdown of proteins and amino acids and, to a fesser extent, lipids and carbohydrates. It is also involved in the metabolism of unsaturated fatty acids and it is also a coenzyme for transaminases and decarboxylases allowing the conversion of tryptophan into nicotinic acid. Pyridoxine is commonly used in form of a sait and particularly in form of its hydrochloride sait. The structure of pyridoxine corresponds to the formula (II):
Doxylamine is commonly used by itself as a short-term sédative and also in combination with other drugs to provide night-time allergy and cold relief. Doxylamine is also used in combination with the analgésies paracétamol (acetaminophen) and codeine as an analgesic/calmative préparation, and is prescribed in combination with pyridoxine to prevent moming sickness in prégnant women.
Modified release oral dosage forms of doxylamine succinate and pyridoxine hydrochloride with different pharmacokinetic and pharmacological properties hâve been disclosed in the state of the art.
Several dual release oral dosage forms of doxylamine succinate and pyridoxine hydrochloride and processes for their préparation hâve been disclosed in the state of the art. These dual reiease oral dosage forms are formed by at least one immédiate release composition and at least one modified release composition having each one of composition one or more of the active ingrédients. This dosage system allows having an immédiate release of one of the active ingrédients and a modified release of the other active ingrédients separately (cf. WO2013123569 and WO2016029290). On the other hand, hard capsules fïlled with modified release pellets of doxylamine succinate and modified release pellets of pyridoxine hydrochloride are marketed with the name of Cariban. Cariban is used for the symptomatic treatment of nausea and vomiting. In particular, the effect of doxylamine and pyridoxine begins to be noted five hours after ingestion, which is advantageous because allows a prolonged therapeutic effect and a réduction of the drug intakes. However, it is not disclosed in the State of the art a process for its préparation.The process used for the préparation of multiple unit oral dosage form (such as tablets or capsules having different plurality of pellets) détermines the pharmacokinetic parameters of the active ingrédients and also the therapeutic activity of the multiple unit dosage form. In particular, the therapeutic effect of the multiple unit dosage forms is conditioned by the dissolution profile of the active ingrédients from each one of the pellets and also from the homogeneity inter-pellets.
Therefore, from what is known in the art it is derived that there is still the need of providing a cheap, robust, reproducible and scaiing-up process for the préparation of homogeneous batches of a multiple unit oral dosage comprising modified release pellets of both active ingrédients doxylamine and pyridoxine, exhibiting the appropriate dissolution profile for being used in therapy.
Summary of Invention
Inventors hâve found that the process for the préparation of the présent invention which comprises coating by spraying (coated) inert nucléus with a mixture of a modified release coating composition and simultaneously applying in solid form the active ingrédient and/or a pore-forming agent (and optionally one or more pharmaceutically acceptable excipient or carrier) at an appropriate spray flow rate allows obtaining homogeneous batches of the multiple unit oral dosage form having modified release pellets of both active ingrédients, doxylamine or a pharmaceutically acceptable sait thereof and pyridoxine or a pharmaceutically acceptable sait thereof, with the appropriate dissolution profile for being used in therapy with a proionged therapeutic effect.ln particular, inventors hâve found that the process for the préparation of a modified release coating of the both plurality of pellets of the présent invention allows that the multiple unit oral dosage form thus obtained exhibits the target dissolution profile, which means thatfrom 10% to 35% by weight of doxylamine content is dissolved at 1sth in 0.1 N HCl medium (pH = 1); then, the medium is replaced by a pH = 4.5 medium (0.05 M acetate buffer) and at 4th h from an accumulated 45% to 70% by weight of doxylamine initial content is dissolved;then, the medium is replaced by a pH = 6.8 medium (0.05 M phosphate buffer) and at 7thh at least an accumulated 80% of doxylamine initial content is dissolved; from 10% to 35% by weight of pyridoxine content is dissolved at 1sth in 0.1 N HCI medium (pH = 1); then, the medium is replaced by a pH = 4.5 medium (0.05 M acetate buffer) and at 4th h from an accumulated 40% to 65% by weight of pyridoxine initial content is dissolved; then, the medium is replaced by a pH = 6.8 medium (0.05 M phosphate buffer) and at 7thh at least an accumulated 80% of pyridoxine initiai content is dissolved; and wherein the dissolution profile is measured using a USP type II apparatus (basket), placing the composition in 900mL ofthe corresponding media / buffer at 37°C ±0.5 °C and 100 rpm.
Thus, the process for the préparation of a modified release coating of the both plurality of pellets of the présent invention allows that the multiple unit oral dosage form thus obtained offers a modified sustained release of both active ingrédients for at least 8 hours after administration. It is advantageous because the modified sustained release composition of the présent invention has a dual effect, one immédiats just after the administration and a proionged release for the entire day, particulariy after getting up. Without being bound to any theory, it seemsthatthe process ofthe invention allows obtaining a homogeneous type of pellets without the formation of aggregates and powdered mixtures which is advantageous for achieving the target dissolution profile. Furthermore, the process of the invention also allows obtaining the both plurality of pellets with a high homogeneity of the content of active ingrédient (i.e. a high inter-pellet homogeneity). It is advantageous because it means that each pellet has about the same amount of active ingrédient and therefore, it assures that the multiple unit oral dosage form filled with those pellets always hâve the therapeutically effective amount of doxylarnine or a pharmaceutically acceptable sait thereof, and pyridoxine or a pharmaceutically acceptable sait thereof. It means that infra- and supra dosification of active ingrédients in the multiple unit oral dosage is avoided by using the process ofthe présent invention.
Finally, inventors hâve also found that the process of the invention is also advantageous because it is cheaper, more robust and reproducible and ease to scale-up in comparison with the processes of the state of the art.
Thus, the aspect of the invention refers to a process for the préparation of a modified release multiple unit oral dosage form comprising: a first plurality of modified release pellets of doxylarnine or a pharmaceutically acceptable sait thereof comprising:
- an inert nucléus;
- an inner active coating layer comprising a therapeutically effective amount of doxylarnine or a pharmaceutically acceptable sait thereof, one or more coating agents and one or more pore-forming agent; and optionally one or more pharmaceutically acceptable excipients;
- an intermediate enteric release coating layer comprising one or more enteric coating agents and one or more pore-forming agent; and
- an external modified release coating layer comprising one or more enteric coating agents, one or more modified release coating agents and one or more pore-forming agent; and a second plurality of modified release pellets of pyridoxine or a pharmaceutically acceptable sait thereof comprising:
- an inert nucléus;
- an inner active coating layer comprising a therapeutically effective amount of pyridoxine or a pharmaceutically acceptable sait thereof, and one or more coating agents; and
- an external modified release coating layer comprising one or more enteric coating agents, one or more modified release coating agents and one or more pore-forming agents;
wherein the process comprises:
- preparing the first plurality of modified release pellets of doxylarnine or a pharmaceutically acceptable sait thereof by coating the pellets of doxylarnine or a pharmaceutically acceptable sait thereof having the inner active coating layer and the intermediate enteric coating layer by simultaneous spraying a mixture comprising from 2.0 to 7.5 % by weight of the enteric coating agents and from 15.0 to 35.0 % by weight of the modified release coating agents in a weight ratio from 5:95 to 30:70; and adding the pore-forming agents in powder form, wherein: the spray flow rate of the mixture comprising the coating agents is from 300 to 1200 mg ! min per kg of inert nucléus; the solid addition rate of the poreforming agents is from 75 to 500 mg/min per Kg of inert nucléus; and the relation between the spray flow rate ofthe mixture comprising the coating agents and the addition rate of the pore-forming agents in solid form is from 90:10 to 60:40; and
- preparing the second plurality of modified release pellets of pyridoxine or a pharmaceutically acceptable sait thereof by coating the pellets of pyridoxine or a pharmaceutically acceptable sait thereof having the inner active coating layer by simultaneous spraying a mixture comprising from 2.0 to 7.5 % by weight of the enteric coating agents and from 15.0 to 35.0 % by weight of the modified release coating agents in a weight ratio from 5:95 to 30:70; and adding the pore-forming agents in powder form, wherein: the spray flow rate of the mixture comprising the coating agents is from 300 to 1200 mg / min per kg of inert nucléus; the solid addition rate of the pore-forming agents is from 75 to 500 mg/min per Kg of inert nucléus; and the relation between the spray flow rate of the mixture comprising the coating agents and the addition rate of the pore-forming agents in solid form is from 90:10 to 60:40.
Detailed description ofthe invention
Ail terms as used herein in this application, unless otherwise stated, shall be understood in their ordinary meaning as known in the art. Other more spécifie définitions for certain terms as used in the présent application are as set forth below and are intended to apply uniformly through-out the spécification and daims unless an otherwise expressly set out définition provides a broader définition. For the purposes ofthe présent invention, any ranges given include both the lower and the upper end-points of the range. Ranges and values given, such as températures, times, and the like, should be considered approximate, unless specifically stated. Furthermore, the terms “relation” and “relationship” hâve the same meaning and are used interchangeable. This term is used in the présent invention for having the relation between the spray flow rate ofthe mixture comprising the coating agents and the addition rate of the pore-forming agents in solid form is from 90:10 to 60:40.
The process of the invention is a process for the préparation of a modified release multiple units oral dosage form containing a plurality of modified release pellets of doxylamine or a pharmaceutically acceptable sait thereof, and modified release pellets of pyridoxine or a pharmaceutically acceptable sait thereof. The term “multiple unit dosage form” defines a dosage form which consists of more than one unit which contains the effective amount of doxylamine and pyridoxine. Usually the multiple unit dosage forms are based on subunits such as granules, pellets or minitablets. They are usually delivered in hard gélatine capsules ortransformed into tablets. In an embodiment, the multiple unit dosage form is a hard capsule filled with pellets as subunits having the active ingrédient.
As it is disclosed above, the process of the invention préparés multiple unit dosage form including two plurality of pellets. The term “pellet” refers to small particies with approximately uniform shapes and sizes produced by an extrusion process or by layercoating of inert nucléus. A “small particle” refers to a particle of which diameter, length, height, width, or the like is from 100 pm to 3000 pm, particularly from 300 pm to 2000 pm; more particularly from 600 pm to 1400 pm. Small particies hâve approximately uniform sizes if the diameter, length, height, width, or the like of the smallest particle is at least about one half ofthe average diameter, length, height, width, orthe like of the particies and if the diameter, length, height, width, or the like of the largest particle is at most about twice the average diameter, length, height, width, or the like of the particies. Then, the term “pellet”, “spherical pellet”, “beads”, “beadlets”, “spherical particies”, “spheroids” and “microspheres” hâve the same meaning and are used interchangeable. The term “granule” refers to small particies without approximately uniform shapes and sizes obtained by a granulation process. Generally, granules are less uniform in size or shape than pellets. Thus, granules hâve a lower uniformity due to their irregular surfaces and afford unacceptable dose uniformity and an inappropriate dissolution profile. Therefore, for the purpose of the invention the term pellet” and “granule” are not the same and they are not interchangeable.
The term “modified release dosage form” and “modified delivery dosage form” as well as “modified release” pellet and “modified delivery” pellet hâve the same meaning and are interchangeable. Both terms are to be understood as a dosage form or pellet that exhibits a slower release of the active agents than that of a conventional immédiate release pharmaceutical composition administered by the same route. In general, the term “modified release” refers that the active ingrédient is released from the pharmaceutical dosage form in a controlled, sustained, prolonged or extended release.
In the context ofthe invention, the term “coating agents” and “film-forming agent coatings” hâve the same meaning and are used interchangeable. Both terms are to be understood as an agent capable of forming a thin polymer-based coat to a solid dosage form such as tablet and pellets. Examples of each one of the types of coating agents are disclosed below.
In particular, the term “modifiée! release coating agent” refers to an agent capable of forming films which allow the delivery of the drug at a predetermined rate and/or location according to the needs of the body and disease States for a definite time of period. Illustrative but nonlimitative exemples of “modified release polymer’ and “modified delivery polymer are polymers which provide a controlled release, a sustained release, a prolonged release or an extended release. Examples of modified release coating agent include without limitation acrylic polymers, celluloses and their dérivatives, shellac, zein, hydrogenated vegetable oil, hydrogenated castor oil, and their mixtures. Examples of suitable acrylic polymers include, but are not limited to, acrylic acid and methacrylic acid copolymers, methyl méthacrylate copolymers, ethoxyethyl méthacrylates, cyanoethyl méthacrylate, aminoalkyl méthacrylate copolymer, poly (acrylic acid), poly (methacrylic acid), methacrylic acid aikyiamide copolymer, poly (methyl méthacrylate), poly (methacrylic acid anhydride), rnethy! méthacrylate, polymethacrylate, poly (methyl méthacrylate) copolymer, polyacrylamide, aminoalkyl méthacrylate copolymer, glycidyl méthacrylate copolymers, shellac, and their mixtures. A modified release polymer is selected from the group consisting of acrylic acid and methacrylic acid copolymers and shellac. Preferably, the modified release polymer is shellac. The modified release polymers can be accompanied by plasticizers such as triethylcitrate (TEC), polyethylene glycol (PEG), cetyl and stearyl alcohol; surface-active agents such as sodium lauryl sulphate, polysorbate and poloxamer; pigments such as titanium dioxide, iron sesquioxide; lubricants such as talc, magnésium stéarate or glyceril monostearate, and mixtures thereof.
The term binder” refers to substances incorporated into formulations to facilitate the agglomération of powder into granules or pellets during mixing with a granulating fluid such as water, hydroalcoholic mixtures, or other solvents. Exemples of binding agents or binders include without limitation microcrystalline cellulose, hydroxypropyl methyl cellulose (HPMC), polyvinyl pyrrolidone (PVP), polyethylene glycol (PEG) 6000^ guar gum, starch or shellac. The term “enteric release” refers to a composition or layer of a dosage form that is formulated to release the active ingredient(s) upon exposure to a characteristic aspect of the gastrointestinal tract. In an embodiment, the enteric material is pH-sensitive and is affected by changes in pH encountered within the gastrointestinal tract (pH-sensitive release). The enteric material typically remains insoluble at gastric pH, then allows for release of the active ingrédient in the higher pH environment of the downstream gastrointestinal tract (e.g. often the duodénum, or sometimes the colon). In another embodiment, the enteric material comprises enzymatically degradable polymers that are degraded by bacterial enzymes présent in the lower gastrointestinal tract, particularly in the coion. Optionally, the unit dosage form is formulated with a pH-sensitive enteric material designed to resuit in a release within about appropriate hours when at or above a spécifie pH. In various embodiments, the spécifie pH can for example be from about 4 to about 7, such as about 4.5, 5, 5.5, 6, 6.5, 6.8 or 7. In the context of the invention, the term “enteric release coating agent” refers to an agent capable of forming films which allow the delivery of doxylamine and pyridoxine upon exposure to a characteristic aspect of the gastrointestinal tract as defined above. Materials used for enteric release formulations, for example as coatings, are well known in the art and include, but are not limited to. cellulosic polymers such as hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl methyl cellulose acetate succinate, hydroxypropylmethyl cellulose phthalate, methylcellulose, ethyl cellulose, cellulose acetate, cellulose acetate phthalate, cellulose acetate trimellitate and carboxymethylcellulose sodium; acrylic acid polymers and copolymers, preferably formed from acrylic acid, methacrylic acid, methyl acrylate, ethyl acrylate, methyl méthacrylate and/or ethyl méthacrylate, and other methacrylic resins that are commercially available under the trade-name Acryl-EZE® (Colorcon, USA), Eudragit® (Rohm Pharma; Westerstadt, Germany), including Eudragit® L30D-55 and L100-55 (soluble at pH 5.5 and above), Eudragit® L100 and L12.5 (soluble at pH 6.0 and above), Eudragit® S, S12,5 and FS 30D (soluble at pH 7.0 and above, as a resuit of a higher degree of estérification), and Eudragits® NE, NM,RL and RS (water- insoluble polymers having different degrees of permeability and expandability); vinyl polymers and copolymers such as polyvinyl pyrroiidone, vinyl acetate, vinyl acetate phthalate, vinyl acetate crotonic acid copolymer, and ethyiene-vinyl acetate copolymer; enzymaticaliy degradable polymers such as azo polymers, pectin, chitosan, amylose and guar gum; zein and sheilac. Combinations of different enteric materials may also be used. Multi-layer coatings using different polymers may also be applied. The properties, manufacture and design of enteric delivery Systems are well known to those of ordinary skill in the art. In a particular embodiment, the enteric coating agent is selected from the group consisting of copolymer of methacrylic acid and methyl méthacrylate, copolymer of methacrylic acid and methyl acrylate, cellulose acetate phthalate, hydroxypropyl methyl cellulose phthalate, polyvinyl acetate phthalate, sodium alginate, cellulose acetate trimellitate and a mixture thereof. More particularly, Eudragit L® such as for example Eudragit L100 (sold by Evonic).
As it is defined above, the process of the présent invention comprises preparing a first plurality of pellets which comprises a therapeutically effective amount of doxylamine or a pharmaceutically acceptable sait thereof and a second plurality of pellets which comprises a therapeutically effective amount of pyridoxine or a pharmaceutically acceptable sait thereof. The term therapeutically effective amount as used herein, refers to the amount of an active ingrédient per multiple unit dosage form that, when administered, is suffîcient to prevent development of, or aHeviate to some extent, one or more of the symptoms of the disease which is addressed. The particular dose of compound administered according to this invention will be determined by the circumstances surrounding the case, including the compound administered, the route of administration, the particular condition being treated, and the similar considérations. The term “pharmaceutically acceptable salt(s)” used herein encompasses any sait formed from pharmaceutically acceptable non-toxic acids including inorganic or organic acids. There is no limitation regarding the salts, except that if used for therapeutic purposes, they must be pharmaceutically acceptable. As doxylamine and pyridoxine are basic compounds, salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Such acids include among others acetic, benzene sulfonic, benzoic, camphor sulfonic, citric, ethansulfonic, fumaric. gluconic, glutamic, hydrobromic, hydrochloric, lactic, maieic, malic, mandelic, methanesulfonic, phosphoric, succinic, sulphuric, tartaric or p-toluensulfonic acid.
The préparation of pharmaceutically acceptable salts of doxylamine and pyridoxine can be carried out by methods known in the art. For instance, they can be prepared from the parent compound, which contains a basic or acidic moiety, by conventional Chemical methods. Generally, such salts are, for example, prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate pharmaceutically acceptable base or acid in water or in an organic solvent or in a mixture of them.
In an embodiment, the process comprises preparing a first plurality of pellets which comprises a therapeutically effective amount of a pharmaceutically acceptable sait of doxylamine, particularly succinate sait of doxylamine. In an embodiment, the process comprises preparing a multiple unit dosage form having the first plurality of pellets which comprises from 5 mg to 50 mg of doxylamine succinate per multiple unit dosage form, particularly from 6 mg to 40 mg, from 7 mg to 30 mg, from 8 mg to 20 mg, and more particularly from 9 mg to 11 mg of doxylamine succinate. In a particular embodiment, the process comprises preparing a multiple unit dosage forms having the first plurality of pellets having 10 mg of doxylamine succinate per multiple unit dosage form. In an embodiment, the process comprises preparing a second plurality of pellets which comprises a therapeutically effective apiount of a pharmaceutically acceptable sait of pyridoxine, particularly pyridoxine hydrochloride. In an embodiment, the process comprises preparing a multiple unit dosage form having the second plurality of pellets which comprises from 5 mg to 50 mg of pyridoxine hydrochloride per multiple unit dosage form, particularly from 6 mg to 40 mg, from 7 mg to 30 mg, from 8 mg to 20 mg, and more particularly from 9 mg to 11 mg of pyridoxine hydrochloride. In a particular embodiment, the process comprises preparing a multiple unit dosage forrns having the first plurality of pellets having 10 mg of pyridoxine hydrochloride per multiple unit dosage form. In an embodiment, the process comprises preparing a multiple unit dosage form comprising the first plurality of pellets which comprises a therapeutically effective amount of a pharmaceutically acceptable sait of doxylarnine, particularly succinate sait of doxylarnine; and the second plurality of pellets which comprises a therapeutically effective amount of a pharmaceutically acceptable sait of pyridoxine, particularly pyridoxine hydrochloride. In an embodiment, the process comprises preparing a multiple unit dosage form comprising the first plurality of pellets which comprises from 5 mg to 50 mg of doxylarnine succinate per multiple unit dosage form, particularly 10 mg of doxylarnine succinate per multiple unit dosage form; and the second plurality of pellets which comprises from 5 mg to 50 mg of pyridoxine hydrochloride per multiple unit dosage form, particularly 10 mg of pyridoxine hydrochloride per multiple unit dosage form. In a particular embodiment, the process comprises preparing the first plurality of pellets which comprises 10 mg of doxylarnine succinate per multiple unit dosage form and the second plurality of pellets comprising 10 mg of pyridoxine hydrochloride per multiple unit dosage form.
In an embodiment, the process comprises preparing a multiple unit dosage form comprising from 20 mg to 220 mg of the first plurality of pellets which comprises a therapeutically effective amount of a pharmaceutically acceptable sait of doxylarnine, particularly succinate sait of doxylarnine; and from 20 mg to 220 mg of the second plurality of pellets which comprises a therapeutically effective amount of a pharmaceutically acceptable sait of pyridoxine, particularly pyridoxine hydrochloride. In an embodiment, the process comprises preparing a multiple unit dosage form comprising from 20 mg to 220 mg, particularly 60mg, of the first plurality of pellets which comprises from 5 mg to 50 mg of doxylarnine succinate, particularly 10 mg of doxylarnine succinate; and from 20 to 220 mg, particularly 60mg, of the second plurality of pellets which comprises from 5 mg to 50 mg of pyridoxine hydrochloride, particularly 10 mg of pyridoxine hydrochloride. In an embodiment, the process comprises preparing a multiple unit dosage form comprising the first plurality of pellets which comprises from 5 mg to 50 mg of doxylarnine succinate, particularly 10 mg of doxylarnine succinate; and the second plurality of pellets which comprises from 5 mg to 50 mg of pyridoxine hydrochloride, particularly 10 mg of pyridoxine hydrochloride. In a particular embodiment, the process comprises preparing the first plurality of pellets which comprises 10 mg of doxylamine succinate and the second plurality of pellets comprising 10 mg of pyridoxine hydrochloride.
in an embodiment, the process comprises preparing a multiple unit dosage form comprising the first plurality of pellets which comprises a therapeutically effective amount of a pharmaceutically acceptable sait of doxylamine having a particle size from 1 pm to 250 pm; particularly from 1 pm to 150 pm; more particularly lower than 100 pm. In an embodiment, the process is one wherein the doxylamine or a sait thereof; particularly doxylamine succinate has a D90 particle diameter from 1 pm to 250 pm; particularly from 1 pm to 150 pm; more particularly lower than 100 pm. The sélection of size ranges or size fractions of particles by sieving is well known. One standard way of defining the particle size distribution in a sample of particles is to refer to D10, D50 and D90 values. D10 is the particle diameter valuesthat 10% ofthe population of particles lies below. D50 isthe particle diametervalues that 50 % of the population lies below and 50% of the population lies above. D50 is also known as the médian particle size value. D90 is the particle diameter values that 90 % of the population lies below.
In an embodiment, the process comprises preparing a multiple unit dosage form comprising the first plurality of pellets which comprises a therapeutically effective amount of a pharmaceutically acceptable sait of pyridoxine having a particle size equal to or lower than 500 pm. In an embodiment. the process is one wherein the pyridoxine or a sait thereof; particularly pyridoxine hydrochloride has a particle size from 1 pm to 250 pm; particularly from 1 pm to 150 pm; more particularly lower than 100 pm. The particle size of the active ingrédients can be measured by any method disclosed in the state of the art. Examples of methods commonly used for measuring the particle size is Dynamic light scattering (DLS) reporting the number average diameter value, Atomic force microscopy (AFM) or transmission électron microscopy (TEM) to measure dried particles; laser diffraction (Laser Masterizer, Mie Theory; ISO 13320-1) and by sédimentation analysis (Sedigraph-Stoke’s Law; ISO 13317-3).
The term “pore-forming agent” refers to any agent capable of forming one or more pores in the shell/coating to allow modified the release of the active ingrédients. The pore-forming agent can be organic or inorganic, or any combination thereof. Examples of pore-forming agent include, but are not limited to, talc, polyethylene glycol (PEG), propylene glycol, isopropyl alcohol, glyceroi, lactose, glucose, sucrose, mannitol, sorbitol, sodium chloride, potassium chloride, hydroxypropyl cellulose, micronized sugar, hydroxypropyl methyl cellulose (HPMC), polyvinyl alcohols, methacrylic acid copolymers, or a mixture therefore. In an embodiment, the pore-forming agent is selected from the group consisting of talc, micronized sugar, sodium or potassium chloride and a mixture thereof. In an embodiment, the process is one wherein the pore-forming agent has a D90 particle diameter equal to or lower than 250 pm; particularly lower than 150 pm; more particularly lower than 100 pm. In a particular embodiment, the process is one wherein the pore-forming agent is talc having a D90 particle diameter lower than 75 pm. The particle size of the pore-forming agent can be measured by any method disclosed in the state of the art. In particular, the method used in the présent invention for measuring the particle size is by laser diffraction (Laser Masterizer, Mie Theory; ISO 13320-1) and by sédimentation analysis (Sedigraph-Stoke’s Law; ISO 13317-3)
The term “inert nucléus” refers to neutral microspheres which can hâve in their composition one or more of the following substances: sorbitoi, mannitol, saccharose, starch, microcrystalline cellulose, lactose, glucose, trehalose, maltitol or fructose. The initiai size of this inert nucléus can be between 200 and 1800 micromètres. In an embodiment, the inert nucleuses are neutral microspheres of a mixture of sucrose and starch.
In an embodiment, the process comprises preparing a multiple unit dosage form which can comprise one or more pharmaceutically acceptable excipients or carriers. The term “pharmaceutically acceptable excipients or carriers” refers to that excipients or carriers suitable for use in the pharmaceutical technology for preparing compositions with medical use. The appropriate excipients and,'or carriers, and their amounts, can readily be determined by those skilied in the art according to the type of formulation being prepared. In an embodiment, the modified release multiple unit dosage form ofthe présent invention further comprises a binder, an alkaline agent, a glidant, a surfactant, or a mixture thereof.
As it is mentioned above, the process of the invention comprises coating separately the pellets of doxylamine or a pharmaceutically acceptable sait thereof having the active layer and the intermediate enteric coating layer; and the pellets of pyridoxine or the pharmaceutically acceptable sait thereof having the inner active coating layer, wherein the modified release coating step comprising: simultaneous spraying a mixture comprising from 2.0 to 7.5 % by weight of the enteric coating agents and from 15.0 to 35.0 % by weight of the modified release coating agents in a weight ratio from 5:95 to 30:70; and adding the pore-forming agents in powder form, wherein: the spray flow rate of the mixture comprising the coating agents is from 300 to 1200 mg / min per kg of inert nucléus; the solid addition rate ofthe pore-forming agents isfrom 75 to 500 mg/min per Kg of inert nucléus, particularly from 85 to 425 mg/min per Kg of inert nucléus; and the relation between the spray flow rate of the mixture comprising the coating agents and the addition rate of the pore-forming agents in solid form is from 90:10 to 60:40. It means that the process is performed by spraying the mixture having the coating agents and at the same time adding the ingrédients that are in powder form. in an embodiment, the process is one wherein the mixture comprising the enteric coating agents and the modified release coating agents as defined in the présent invention has a weight ratio from 5:95 to 30:70. In an embodiment. the process is one as defined above wherein the mixture comprises methacrylic acid-methyl méthacrylate copolymer (1:1) (Eudragit L) as enteric coating agent and (dewaxed) shellac as modified release coating agent in a weight ratio from 5:95 to 30:70; particularly from 8:92 to 20:80. In an embodiment, the process is one wherein the spray flow rate of the mixture comprising the coating agents is from 300 to 1200 mg/min per Kg of inert nucléus; particularly from 385 to 1000g/min per Kg of inert nucléus.
In an embodiment, the process ofthe invention comprises coating separately the pellets of doxylamine or a pharmaceutically acceptable sait thereof having the active layer and the intermediate enteric coating layer as defined above; then the process is one wherein the solid addition rate of the pore-forming agents is from 88 to 195 mg/min per Kg of inert nucléus. In an embodiment, the process is one wherein the relation between the spray flow rate of the mixture comprising the coating agents and the solid addition rate of the poreforming agents is from 90:10 to 60:40; particularly from 90:10 to 70:30. In an embodiment, the process is one wherein the mixture comprising from 2.5 to 7.5% of the enteric coating agents and from 15 to 30% of the modified release coating agents is a solution further comprising one or more organic solvents; particularly in an amount from 85 to 290 g of solvent per Kg of inert nucléus; particularly from 250 to 290 g of solvent per Kg of inert nucléus; more particularly from 270 to 285 g of solvent per Kg of inert nucléus. In an embodiment, the process of the invention comprises coating separately the pellets of pyridoxine or the pharmaceutically acceptable sait thereof having the inner active coating layer, then the process is one wherein the solid addition rate of the pore-forming agents is from 193 to 425 mg/min per Kg of inert nucléus. In an embodiment, the process is one wherein the relation between the spray flow rate of the mixture comprising the coating agents and the solid addition rate of the pore-forming agents is from 90:10 to 60:40; particularly from 80:20 to 60:40. In an embodiment, the process is one wherein the mixture comprises from 2.5 to 5.5% ofthe enteric coating agents and from 20 to 35% ofthe modified release coating agents is a solution further comprising one or more organic solvents;
particuiariy in an amount from 85 to 100 g of solvent per Kg of inert nucléus; particularly from 90 to 95 g of solvent per Kg of inert nucléus; more particularly from 280 to 290 g of solvent per Kg of inert nucléus.
In an embodiment, the process of the invention comprises coating separateiy the pellets of doxylamine or a pharmaceutically acceptable sait thereof having the active layer and the intermediate enteric coating layer as defined above; or the pellets of pyridoxine or the pharmaceutically acceptable sait thereof having tire inner active coating layer, is one wherein the mixture comprising the enteric coating agents and the modified release coating 10 agents is a solution further comprising one or more organic solvents selected from the group consisting of (Ci-C^alœhot (Ci-C^alkyl-CO-fCi-C^alkyl, (CrC4)alkyl-CO-O-(CiC4)alkyl, water and mixtures thereof, The term “alcohol” refers to an “alkane” wherein at least one hydrogen atom is substituted by a hydroxyl group and which contains the number of carbon atoms specified in the description or claims. The term alkane refers to a 15 saturated, branched or linear hydrocarbon which contains the number of carbon atoms specified in the description or claims. Examples include methanol, éthanol, n-propanol, isopropanol, butanol, iso-butanol, and sec-butanol. The term “alkyl” refers to a saturated straight, or branched hydrocarbon chain which contains the number of carbon atoms specified in the description or claims. Exemples include, among others, the group methyl, 20 ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl. In an embodiment, the process is one wherein the mixture comprising the enteric coating agents and the modified release coating agents is a solution further comprising one or more organic solvents selected from the group consisting of éthanol, 2-propanol, methanol, acetone, butanone, ethyl acetate, water and a mixture thereof; particularly selected from éthanol, acetone, 25 water and a mixture thereof.
In an embodiment, the process ofthe invention comprises coating separateiy the pellets of doxylamine or a pharmaceutically acceptable sait thereof having the active layer and the intermediate enteric coating layer, and the pellets of pyridoxine or the pharmaceutically 30 acceptable sait thereof having the inner active coating layer, wherein the airflow is from 0 a 20 m3/h per Kg of inert nucléus; particularly from O to 4 m3 /h per Kg of inert nucléus. The airflow is controlled using an anemometer type air inlet détection system installed in the duct between the fan and the coating pan, or using another équivalent system.
In an embodiment, the process ofthe invention comprises coating separateiy the pellets of doxylamine or a pharmaceuticaliy acceptable sait thereof having the active layer and the intermediate enteric coating layer; and the pellets of pyridoxine or the pharmaceutically acceptable sait thereof having the inner active coating layer, wherein the core température of the pellets during the coating step is from 5°C to 50 °C; particularly from 10°C to 30°C; more particularly from 15°C to 25 °C. The température is controlled using a calibrated PT100 sensor being directly in contact with the pellets being coated, but it could be controlled using an équivalent System.
In an embodiment, the process ofthe invention comprises coating separately the pellets of doxylamine or a pharmaceutically acceptable sait thereof having the inner active coating layer and the intermediate enteric coating layer; and the pellets of pyridoxine or the pharmaceutically acceptable sait thereof having the inner active coating layer, wherein the rotation speed is from 0 to 50 rpm, particularly from 2 to 25 rpm; more particularly from 10 to 20 rpm. The rotation pan speed can be controlled by any method known in the state of the art. In particular, the method used in the présent invention is by using a révolution counter.
In an embodiment. wherein the process ofthe invention comprises coating the pellets of doxylamine or a pharmaceutically acceptable sait thereof having the inner active coating layer and the intermediate enteric coating layer; then the coating step comprising: spraying a mixture comprising from 2.0 to 7.5 % by weight of the enteric coating agents and from 15% to 35 % by weight of the modified release coating agents; wherein the weight ratio between the enteric coating agents and the modified release coating agents is from 15:85 to 25:75. Particularly, the mixture comprises from 4 to 7% by weight of the methacrylic acid-methyl méthacrylate copolymer (1:1) (Eudragit L) as enteric coating agent and from 15 to 25 % by weight of (dewaxed) sheliac as modified release coating agent in a weight ratio from 15:85 to 25:75.
In an embodiment, wherein the process ofthe invention comprises coating the pellets of pyridoxine or the pharmaceutically acceptable sait thereof having the inner active coating layer; then the coating step comprising: spraying the mixture comprising from 2.0 to 7.5% by weight ofthe enteric coating agents and from 15 to 35%, panicuiarly from 20 to 35%, of the modified release coating agents wherein the weight ratio between the enteric coating agents and the modified release coating agents is from 5:95 to 30:70. Particularly, the mixture comprises from 2.0 to 5% by weight of methacrylic acid-methyl méthacrylate copolymer (1:1) (Eudragit L) as enteric coating agent and from 25 to 35% by weight of (dewaxed) sheliac as modified release coating agent in a weight ratio from 5:95 to 15:85.
in an embodiment, wherein the process of the invention comprises coating the peilets of doxylamine or a pharmaceutically acceptable sait thereof having the inner active coating layer and the intermediate enteric coating layer; then the coating step comprising simultaneously spraying a mixture comprising from 2.0 to 7.5% by weight of the enteric coating agents and from 15 to 35% by weight of the modified release coating agents in a weight ratio from 5:95 to 30:70; and adding the pore-forming agents in powder form, wherein: the spray flow rate of the mixture comprising the coating agents is from 300 to 1200 mg/min per Kg of inert nucléus; particularly from 445 to 1000 g/min per Kg of inert nucléus; more particularly about 890 mg/min kg pellets; the solid addition rate of the poreforming agents is from 88 to 195 mg/min per Kg of inert nucléus, more particularly 178 mg/min per kg pellets; and the relation between the spray flow rate of the mixture comprising the coating agents and the solid addition rate of the pore-forming agents is from 90:10 to 70:30, particularly frorn 85:15 to 75:25, more particularly 83:17. It rneans that the process is performed by spraying the mixture having the coating agents and at the same time adding the ingrédients that are in powder form. In an embodiment, the process is one wherein the mixture comprising the enteric coating agents and the modified release coating agents as defined in the présent invention has a weight ratio from 10:90 to 30:70, particularly from 15:85 to 25:75. In an embodiment, the process is one wherein the mixture comprises methacrylic acid-methyl méthacrylate copolymer (1:1) (Eudragit L) as enteric coating agent and (dewaxed) shellac as modified release coating agent in a weight ratio from 15:85 to 25:75; particularly from 18:82 to 22:78 and more particularly 20:80. In an embodiment, the process is one wherein the spray flow rate of the mixture comprising the coating agents is from 300 to 1200 mg/min per Kg of inert nucléus; particularly from 445 to 1000 mg/min per Kg of inert nucléus, more particularly 890 mg/min per Kg pellets. In an embodiment, the process is one wherein the solid addition rate of the pore-forming agents is from 88 to 195 mg/min per Kg of inert nucléus, more particularly 178 mg/min per kg pellets. In an embodiment, the process is one wherein the relation between the spray flow rate of the mixture comprising the coating agents and the solid addition rate of the poreforming agents from 85:15 to 75:25, particularly 83:17. In an embodiment, the process is one wherein the mixture comprising from 2 to 7.5% by weight of the enteric coating agents are as defined above, particularly is methacrylic acid-methyl méthacrylate copolymer (Eudragit L), and from 15 to 35% by weight of the modified release coating agents is a solution further comprising one or more organic solvents; particularly in an amount of solvents from 275 to 290 g/min per Kg of pellet, more particularly 282 g/kg pellet, having the mixture an overall solvent concentration from 72 to 78% by weigh. In an embodiment, the process is one wherein the mixture comprising the enteric coating agents and the modified release coating agents is a solution further comprising one or more organic solvents as defined above. In an embodiment, wherein the process of the invention comprises coating the pellets of pyridoxine or the pharmaceutically acceptable sait thereof having the inner active coating layer; then the coating step comprising: simuïtaneous spraying a mixture comprising from 2.0 to 7.5 %; particularly from 2 to 5.5%, by weight of the enteric coating agents and from 15 to 35 % by weight of the modified release coating agents in a weight ratio from 5:95 to 25:75; and adding the pore-forming agents in powder form, wherein: the spray flow rate of the mixture comprising the coating agents is from 385 to 850 mg/min per Kg of inert nucléus; the solid addition rate ofthe pore-forming agents is from 193 to 425 mg/min per Kg of inert nucléus; and the relation between the spray flow rate of the mixture comprising the coating agents and the solid addition rate of the poreforming agents is from 80:20 to 60:40. It means that the process is performed by spraying the mixture having the coating agents and at the same time adding the ingrédients that are in powder form. In an embodiment, the process is one wherein the mixture comprising the enteric coating agents and the modified release coating agents as defined in the présent invention has a weight ratio from 5:95 to 30:70. In an embodiment, the process is one wherein the mixture comprises methacrylic acid-methyl méthacrylate copolymer (1:1) (Eudragit L) as enteric coating agent and (dewaxed) shellac as modified release coating agent in a weight ratio from 5:95 to 25:75; particularly from 5:95 to 15:85 and more particularly 9:91. In an embodiment, the process is one wherein the spray flow rate of the mixture comprising the coating agents is from 385 to 850 mg/min per Kg of inert nucléus; particulariy 773 mg/min per Kg of inert nucléus. ïn an embodiment, the process is one wherein the solid addition rate of the pore-forming agents; particularly talc, is from 193 to 425 mg/min per Kg of inert nucléus; particularly 387 mg/min per Kg of inert nucléus. In an embodiment, the process is one wherein the relation between the spray flow rate of the mixture comprising the coating agents and the solid addition rate of the pore-forming agents is from 90:10 to 60:40; particularly from 75:25 to 65:35, more particularly 67:33. In an embodiment, the process is one wherein the mixture comprising from 2.0 to 7.5% of the enteric coating agents and from 15 to 35% of the modified release coating agents is a solution further comprising one or more organic solvents; particulariy in an overall amount of solvents from 90 to 95 g per Kg of pellet, more particulariy 93 g/kg peîîet, having the mixture an overall solvent concentration from 65 to 70% by weigh, more particularly a 68% by weight of solvents. In an embodiment, the process is one wherein the mixture comprising the enteric coating agents and the modified release coating agents is a solution further comprising one or more organic solvents as defined above.
In an embodiment, the process ofthe invention further comprises a previous step of coating separately the inert nucléus with a simultaneous spraying of a mixture comprising from 30 to 40% by weight one or more coating agents and adding a powdered mixture of the therapeutically effective amount of doxylamine or a pharmaceuticaily acceptable sait thereof, particularly doxylamine succinate, from 22 to 30% by weight of the pore-forming agents, and optionally one or more pharmaceutically acceptable excipients; wherein the spray flow rate of the mixture comprising from 30 to 40% by weight one or more coating agents is from 445 to 1000 mg/min per Kg of inert nucléus; the solid addition rate of the powdered mixture is from 1.64 to 3.62 g/min per Kg of inert nucléus; and the relation between the spray flow rate of the mixture comprising the coating agents and the solid addition rate of the powdered mixture is from 15:85 to 25:75. In an embodiment, the process is one wherein the mixture comprising from 30 to 40% by weight of one or more of the coating agents is a solution further comprising one or more organic solvents; particularly in an amount from 60 to 70% by weight. In an embodiment, the process is one wherein the mixture comprising the coating agents is a solution further comprising one or more organic solvents selected from the group consisting of éthanol, 2-propanol, methanol, acetone, butanone, ethyl acetate and water or a mixture thereof.
In an embodiment, the process ofthe invention further comprises a previous step of coating separately the inert nucléus with a simultaneous spraying of a mixture comprising from 30 to 40% by weight one or more coating agents and adding a powdered mixture of the therapeutically effective amount of doxylamine or a pharmaceuticaily acceptable sait thereof, particularly doxylamine succinate, from 22 to 30% by weight of the pore-forming agents, and optionally one or more pharmaceutically acceptable excipients; wherein the spray flow rate of the mixture comprising from 30 to 40% by weight one or more coating agents is from 445 to 1000 mg/min per Kg of inert nucléus; the solid addition rate of the powdered mixture is from 1.64 to 3.62 g/min per Kg of inert nucléus; and the relation between the spray flow rate of the mixture comprising the coating agents and the solid addition rate ofthe powdered mixture is from 15:85 to 25:75; wherein the coating agent is selected from the group consisting of polyvinylpyrrolidone, shellac, hyproxypropylmethylceliulose, hydroxypropylcellulose, and microcrystalline cellulose and mixture thereof; particularly a mixture of polyvinylpyrrolidone and shellac. Particularly, the mixture comprising from 30 to 40% by weight of one or more coating agents is a mixture of polyvinylpyrrolidone K30 and (dewaxed) shellac in a weight ratio from 10:90 to 18:82 of solid coating agents (this values are équivalent to a weight ratio from polyvinylpyrrolidone and shellac from 20:80 to 30:70). More particularly, a mixture of a solution of polyvinylpyrrolidone K-30 20% in éthanol and a solution of (dewaxed) sheliac 40% w/w in éthanol in a weight ratio from 20:80 to 40:60; particularly 30:70. In an embodiment, the process of the invention further comprises a previous step of coating separately the inert nucléus with a simultaneous spraying of a mixture comprising from 30 to 40 % by weight of one or more coating agents and adding a powdered mixture of the therapeutically effective amount of doxylarnine or a pharmaceutically acceptable sait thereof, particularly doxylarnine succinate, from 22 to 30% by weight of the pore-forming agents, and optionally one or more pharmaceutically acceptable excipients; wherein the spray flow rate of the mixture comprising from 30 to 40% by weight one or more coating agents is from 445 to 1000 mg/min per Kg of inert nucléus; the solid addition rate ofthe powdered mixture isfrom 1.64 to 3.62 g/min per Kg of inert nucléus; and the relation between the spray flow rate of the mixture comprising the coating agents and the solid addition rate of the powdered mixture is from 15:85 to 30:70. In an embodiment, the process is one wherein the mixture comprising from 30 to 40% by weight of one or more of the coating agents is a solution further comprising one or more organic solvents; particularly in an overall amount of solvents from 61 to 71 g per Kg of inert nucléus, more particularly 66 g per Kg of inert nucléus, having the mixture an overall solvent concentration from 0 to 70% by weight. In an embodiment, the process is one wherein the pore-forming agent is selected from talc, micronized sugar, sodium or potassium chloride and a mixture thereof; particularly talc. In an embodiment, the process is one wherein the mixture comprising the coating agents is a solution further comprising one or more organic solvents as defined above. In an embodiment, the process of the invention further comprises a previous step of coating separately the inert nucléus with a simultaneous spraying of a mixture comprising from 30 to 40% by weight of one or more coating agents and adding a powdered mixture of the therapeutically effective amount of doxylarnine or a pharmaceutically acceptable sait thereof, particularly doxylarnine succinate, from 22 to 30% by weight of the pore-forming agents, and optionally one or more pharmaceutically acceptable excipients as defined above wherein the pharmaceutically acceptable excipient is selected from the group consisting of one or more glidant, fillers, wicking agents or mixtures thereof.
The term “glidant” refers to a substance which improves the flow characteristics of powder mixtures in the dry state. Materials commonly used as a glidant include magnésium stéarate, colloïdal Silicon dioxide or talc. In an embodiment, the composition ofthe invention is one wherein the pharmaceutically acceptable excipients or carriers comprises one or more glidant: preferably comprises colloïdal Silicon dioxide, and more preferably Aerosil 200 Pharma. The term “filler” refers to materiais that are added to bulk-up a dosage form when the active ingrédient is no présent in sufficient quantity. Materials commonly used as filler include lactose, sucrose, mannitol, dicalcium phosphate dehydrate, starch, cellulose and microcrystalline cellulose. In an embodiment, the composition ofthe invention is one wherein the pharmaceutically acceptable excipients or carriers comprises one or more fillers; preferably comprises sucrose, starch or microcrystalline cellulose. The term “wicking agents” refers to the material that has the ability to draw water into the porous network of a delivery device. It has the ability to undergo physiosorption with water. The rôle of a wicking agent is to act like a carrier and facilitate the entry of water to the inner surfaces of the core. Materials commonly used as wicking agent include sodium lauryl sulfate, kaolin, titanium dioxide, alumina, bentonite, magnésium aluminium silicate, povidone and colloïdal Silicon dioxide (Aerosil). In an embodiment, the composition ofthe invention is one wherein the pharmaceutically acceptable excipients or carriers comprises one or more wicking agents; preferably kaolin, titanium dioxide, alumina, bentonite, magnésium aluminium silicate, povidone and colloïdal Silicon dioxide (Aerosil). In an embodiment, the composition of the invention is one wherein the pharmaceutically acceptable excipients or carriers comprises one or more wicking agents; preferably comprises povidone or colloïdal Silicon dioxide (Aerosil) or a mixture thereof.
In an embodiment, the process ofthe invention further comprises a previous step of coating separately the inert nucléus with a simultaneous spraying of a mixture comprising from 30 to 40% by weight of one or more coating agents and adding a powdered mixture of the therapeutically effective amount of doxyiamine or a pharmaceuticalïy acceptable sait thereof, particularly doxyiamine succinate, from 22 to 30% by weight of the pore-forming agents, and one or more pharmaceutically acceptable excipients as defined above, wherein the spray flow rate of the mixture comprising from 30 to 40 % by weight of one or more coating agents is from 445 to 1000 mg/min per Kg of inert nucléus; the spray flow of the powdered mixture is from 1.64 to 3.62 g/min per Kg of inert nucléus; and the relation between the spray flow rate of the mixture comprising the coating agents and the solid addition rate powdered mixture is from 15:85 to 30:70. In an embodiment, doxyiamine or a pharmaceutically acceptable sait thereof, particularly doxyiamine succinate, has a particle size equal to or lowers than 100 pm. In an embodiment, the process ofthe invention further comprises a previous step of coating separately the inert nucléus with a simultaneous spraying of a mixture comprising from 30 to 45% of one or more coating agents and adding the therapeutically effective amount of pyridoxine or a pharmaceutically acceptable sait thereof; particularly pyridoxine hydrochloride, in powder form: wherein the spray flow rate of the mixture comprising from 30 to 45% of one or more coating agents, particularly 40% of (dewaxed) shellac in éthanol, is from 385 to 850 mg/min per Kg of inert nucléus; the solid addition rate of the powder is from 770 to 1700 mg /min per Kg of inert nucléus; and the relation between the spray flow rate of the mixture comprising the coating agents and the powdered mixture is from 25:75 to 40:60. In an embodiment, the process ofthe invention further comprises a previous step of coating separately the inert nucléus with a simultaneous spraying of a mixture comprising from 30 to 45% by weight of one or more coating agents and adding the therapeutically effective amount of pyridoxine or a pharmaceutically acceptable sait thereof, particularly pyridoxine hydrochloride, in powder form: wherein the spray flow rate of the mixture comprising from 30 to 45% of one or more coating agents is from 385 to 850 mg/min per Kg of inert nucléus; the solid addition rate of the powder is from 770 to 1700 mg/min per Kg of inert nucléus; and the relation between the spray flow rate of the mixture comprising the coating agents and the solid addition rate of powdered mixture is from 25:75 to 40:60; and the coating agent is selected from the group consisting of microcrystalline cellulose, hydroxypropyl methyl cellulose (HPMC), polyvinyl pyrrolidone (PVP), shellac, polyethylene glycol (PEG) 6000, guargum and starch; particularly (dewaxed) shellac.
In an embodiment, the process of the invention further comprises a previous step of coating separately the inert nucléus with a simultaneous spraying of a mixture comprising from 30 to 45% by weight of one or rnore coating agents and adding the therapeutically effective amount of pyridoxine or a pharmaceutically acceptable sait thereof; particularly pyridoxine hydrochloride, in power form: wherein the spray flow rate of the mixture comprising from 30 to 45% by weight of one or more coating agents is from 385 to 850 mg/min per Kg of inert nucléus: the solid addition rate of the powder is from 770 to 1700 mg/min per Kg of inert nucléus; and the relation between the spray flow rate of the mixture comprising the coating agents and the solid addition rate of powdered mixture is from 25:75 to 40:60; and the weight ratio between the therapeutically effective amount of pyridoxine or a pharmaceutically acceptable sait thereof: particularly pyridoxine hydrochloride in powder form and the mixture comprising the coating agents is from 25:75 to 40:60; particularly a weight ratio of 1:2. In an embodiment, the process of the invention further comprises a previous step of coating separately the inert nucléus with a simultaneous spraying of a mixture comprising from 30 to 45% by weight of one or more coating agents and adding the therapeutically effective amount of pyridoxine or a pharmaceutically acceptable sait thereof; particularly pyridoxine hydrochloride in power form; wherein the spray flow rate of the mixture comprising from 30 to 45% by weight of one or more coating agents is from 385 to 850 mg/min per Kg of inert nucléus; the solid addition rate of the powder is from 770 to 1700 mg/min per Kg of inert nucieus; and the relation between the spray flow rate of the mixture comprising the coating agents and the solid addition rate of the powdered mixture is from 25:75 to 40:60 and pyridoxine or a pharmaceutically acceptable sait thereof; particularly pyridoxine hydrochloride, has a particle size equal to or lower than 100 pm.
In an embodiment, the process ofthe invention further comprises a previous step of coating separately the inert nucieus with a simultaneous spraying of a mixture comprising from 30 to 45% by weight of one or more coating agents and adding the therapeutically effective amount of pyridoxine or a pharmaceutically acceptable sait thereof is one wherein the mixture comprising one or more coating agents is a solution further comprising one or more organic solvents; particularly in an amount of solvents from 65 to 83 g/kg of pellet, more particularly 71 g/kg pellets, having the mixture an overall solvent concentration from 55 to 70% by weigh, more particularly a 60% by weight of solvents. In an embodiment, the process is one wherein the mixture comprising the coating agents is a solution further comprising one or more organic solvents as defined above. In an embodiment, the process of the invention further comprises an additional step which comprises coating the pellets of doxylamine or a pharmaceutically acceptable sait thereof; particularly doxylamine succinate, having the inner active coating layer by simultaneous spraying of a mixture comprising from 5 to 15% by weight of one or more enteric coating agents and adding from 5.5 to 6.0 g per kg of inert nucieus of the pore-forming agents in powder form wherein the spray flow rate of the mixture comprising from 5 to 15% by weight of one or more enteric coating agents is from 445 to 1000 mg/min per Kg of inert nucieus; the solid addition rate of the pore forming agent is from 45 to 100 mg/min per Kg of inert nucieus; and the relation between the spray flow rate of the mixture comprising the coating agents and the solid addition rate is from 87:13 to 93:7.
In an embodiment, the process ofthe invention further comprises an additional step which comprises coating the pellets of doxylamine or a pharmaceutically acceptable sait thereof, particularly doxylamine succinate, having the inner active coating layer by simultaneous spraying of a mixture comprising from 5 to 15% of the enteric coating agents and adding from 5.5 to 6.0 g per kg of inert nucieus of the pore-forming agents in powder form; wherein the spray flow rate of the mixture comprising from 5 to 15% by weight of one or more enteric coating agents is from 445 to 1000 mg/min per kg of inert nucieus: the solid addition rate of the pore forming agent is from 45 to 100 mg/min per Kg of inert nucieus; and the relation between the spray flow rate of the mixture comprising the coating agents and the solid addition rate is from 87:13 to 93:7 and the enteric coating agents are as defined above, particularly is methacrylic acid-methyl méthacrylate copolymer (Eudragit L). In an embodiment, the process of the invention further comprises an additional step which comprises coating the pellets of doxylamine or a pharmaceutically acceptable sait thereof, particularly doxylamine succinate, having the inner active release coating layer by simultaneous spraying of a mixture comprising from 5 to 15% by weight of the enteric coating agents and adding from 5.5 to 6.0 g per Kg of inert nucléus of the pore-forming agents in powder form; wherein the spray flow rate of the mixture comprising from 5 to 15% of one or more enteric coating agents is from 445 to 1000 mg/min per kg of inert nucléus, particularly 910 mg/min per kg of inert nucléus; the solid addition rate of the pore forming agent is from 45 to 100 mg/min per kg of inert nucléus; and the relation between the spray flow of the mixture comprising the coating agents and the powdered mixture is from 87:13 to 93:7, particularly 90:10; and the pore-forming agent is as defined above, particularly talc.
In an embodiment, the process ofthe invention further comprises an additional step which comprises coating the pellets of doxylamine or a pharmaceutically acceptable sait thereof, particularly doxylamine succinate, having the inner active release coating layer by simultaneous spraying of a mixture comprising from 5 to 15% by weight of the enteric coating agents and adding from 5.5 to 6.0 g per kg of inert nucieus, particularly 5.7 g per kg of inert nucieus, of the pore-forming agents in powder form, wherein the mixture comprising from 5 to 15% by weight of the enteric coating agents is a mixture further comprising one or more organic solvents; particularly in an overall amount of solvents from 48 to 55 g per kg of inert nucieus, more particularly 51g per kg of inert nucieus, having the mixture an overall solvents concentration of 85 to 95% by weight, more particularly in a 90% by weight of solvents. In an embodiment, the process is one wherein the mixture comprising the coating agents is a solution further comprising one or more organic solvents as defined above.
In an embodiment, the process ofthe présent invention which comprises preparing the first plurality of modified release pellets of doxylamine or a pharmaceutically acceptable sait thereof by:
- coating the pellets of doxylamine or a pharmaceutically acceptable sait thereof having the inner active coating layer and the intermediate enteric coating layer by simultaneous spraying a mixture comprising from 2.0 to 7.5 % by weight of the enteric coating agents and from 15.0 to 35.0 % by weight of the modified release coating agents in a weight ratio from 5:95 to 30:70; and adding the pore-forming agents in powder form, wherein: the spray flow rate of the mixture comprising the coating agents is from 300 to 1200 mg / min per kg of inert nucieus; the solid addition rate of the pore-forming agents is from 75 to 500 mg/min per Kg of inert nucléus, particularly from 85 to 425 mg/min per Kg of inert nucléus; and the relation between the spray flow rate of the mixture comprising the coating agents and the addition rate of the pore-forming agents in solid form îs from 90:10 to 60:40.
In an embodiment, the process ofthe présent invention which comprises preparing the first plurality of modified release pellets of doxylamine or a pharmaceutically acceptable sait thereof by:
- coating the pellets of doxylamine or a pharmaceutically acceptable sait thereof having the inner active release coating layer by simultaneous spraying of a mixture comprising from 5 to 15% of the enteric coating agents and adding from 5.5 to 6.0 g per kg of inert nucléus of the pore-forming agents in powder form; wherein the spray flow rate of the mixture comprising from 5 to 15% by weight of one or more enteric coating agents is from 445 to 1000 mg/min per kg of inert nucléus; the solid addition rate of the pore forming agent is from 45 to 100 mg/min per Kg of inert nucléus; and the relation between the spray flow rate of the mixture comprising the coating agents and the solid addition rate is from 87:13 to 93:7; and
- coating the pellets of doxylamine or a pharmaceutically acceptable sait thereof having the inner active coating layer and the intermediate enteric coating layer by simultaneous spraying a mixture comprising from 2.0 to 7.5 % by weight of the enteric coating agents and from 15.0 to 35,0 % by weight of the modified release coating agents in a weight ratio from 5:95 to 30:70; and adding the pore-forming agents in powder form, wherein: the spray flow rate of the mixture comprising the coating agents is from 300 to 1200 mg / min per kg of inert nucléus; the solid addition rate ofthe pore-forming agents isfrom 75 to 500 mg/min per Kg of inert nucléus, particularly from 85 to 425 mg/min per Kg of inert nucléus; and the relation between the spray flow rate of the mixture comprising the coating agents and the addition rate ofthe pore-forming agents in solid form is from 90:10 to 60:40.
In an embodiment, the process ofthe présent invention which comprises preparing the first plurality of modified release pellets of doxylamine or a pharmaceutically acceptable sait thereof by:
-coating separately the inert nucléus with a simultaneous spraying of a mixture comprising from 30 to 40% by weight one or more coating agents and adding a powdered mixture of the therapeutically effective amount of doxylamine or a pharmaceutically acceptable sait thereof, from 22 to 30% by weight of the pore-forming agents, and optionally one or more pharmaceutically acceptable excipients; wherein the spray flow rate of the mixture comprising from 30 to 40% by weight one or more coating agents is from 445 to 1000 mg/min per Kg of inert nucléus; the solid addition rate ofthe powdered mixture is from 1.64 to 3.62 g/min per Kg of inert nucléus; and the relation between the spray flow rate of the mixture comprising the coating agents and the solid addition rate of the powdered mixture is from 15:85 to 25:75;
- coating the pellets of doxylamine or a pharmaceutically acceptable sait thereof having the inner active coating layer by simultaneous spraying of a mixture comprising from 5 to 15% of the enteric coating agents and adding from 5.5 to 6.0 g per kg of inert nucléus of the pore-forming agents in powder form; wherein the spray flow rate of the mixture comprising from 5 to 15% by weight of one or more enteric coating agents is from 445 to 1000 mg/min per kg of inert nucléus; the solid addition rate of the pore forming agent is from 45 to 100 mg/min per Kg of inert nucléus; and the relation between the spray flow rate of the mixture comprising the coating agents and the solid addition rate is from 87:13 to 93:7; and - coating the pellets of doxylamine or a pharmaceutically acceptable sait thereof having the inner active coating layer and the intermediate enteric coating layer by simultaneous spraying a mixture comprising from 2.0 to 7.5 % by weight of the enteric coating agents and from 15.0 to 35.0 % by weight ofthe modified release coating agents in a weight ratio from 5:95 to 30:70; and adding the pore-forming agents in powder form, wherein: the spray flow rate of the mixture comprising the coating agents is from 300 to 1200 mg ! min per kg of inert nucléus; the solid addition rate of the pore-forming agents is from 75 to 500 mg/min per Kg of inert nucléus, particularly from 85 to 425 mg/min per Kg of inert nucléus; and the relation between the spray flow rate of the mixture comprising the coating agents and the addition rate ofthe pore-forming agents in solid form is from 90:10 to 60:40.
In an embodiment, the process of the présent invention which comprises preparing the second plurality of modified release pellets of pyridoxine or a pharmaceutically acceptable sait thereof by:
-coating the pellets of pyridoxine or a pharmaceutically acceptable sait thereof; particularly doxylamine succinate, having the inner active coating layer by simultaneous spraying simultaneous spraying a mixture comprising from 2.0 to 7.5 % by weight of the enteric coating agents and from 15.0 to 35.0 % by weight of the modified release coating agents in a weight ratio from 5:95 to 30:70; and adding the pore-forming agents in powder form, wherein: the spray flow rate of the mixture comprising the coating agents is from 300 to 1200 mg ! min per kg of inert nucléus; the solid addition rate ofthe pore-forming agents is from 75 to 500 mg/min per Kg of inert nucléus, particularly from 85 to 425 mg/min per Kg of inert nucléus; and the relation between the spray flow rate of the mixture comprising the coating agents and the addition rate of the pore-forming agents in solid form is from 90:10 to 60:40.
ïn an embodiment, the process of the présent invention which comprises preparing the second plurality of modified release pellets of pyridoxine or a pharmaceutically acceptable sait thereof by;
-coating separately the inert nucléus with a simultaneous spraying of a mixture comprising from 30 to 45% of one or more coating agents and adding the therapeutically effective amount of pyridoxine or a pharmaceutically acceptable sait thereof in powder form: wherein the spray flow rate ofthe mixture comprising from 30 to 45% of one or more coating agents is from 385 to 850 mg/min per Kg of inert nucléus; the solid addition rate of the powder is from 770 to 1700 mg /min per Kg of inert nucléus; and the relation between the spray flow rate of the mixture comprising the coating agents and the powdered mixture is from 25:75 to 40:60; and
-coating the pellets of pyridoxine or a pharmaceutically acceptable sait thereof; particularly doxylamine succinate, having the inner active coating layer by simultaneous spraying simultaneous spraying a mixture comprising from 2.0 to 7.5 % by weight of the enteric coating agents and from 15.0 to 35.0 % by weight of the modified release coating agents in a weight ratio from 5:95 to 30:70; and adding the pore-forming agents in powder form, wherein: the spray flow rate of the mixture comprising the coating agents is from 300 to 1200 mg / min per kg of inert nucléus: the solid addition rate of the pore-forming agents is from 75 to 500 mg/min per Kg of inert nucléus, particulariy from 85 to 425 mg/min per Kg of inert nucléus; and the relation between the spray flow rate of the mixture comprising the coating agents and the addition rate of the pore-forming agents in solid form is from 90:10 to 60:40.
In an embodiment, each one of the coating steps are performed at a température from 10°C to 30°C; particularly from 15°C to 25°C; more particularly from 17°C to 22°C. In an embodiment, each one of the coating steps are performed at an airflow from 0 a 20 m3/h per Kg of inert nucléus; particularly from 0 to 4 m3 /h per Kg of inert nucléus. The airflow is controlled using an anemometer type air inlet détection system installed in the duct between the fan and the coating pan, or using another équivalent system. In an embodiment, the process ofthe présent invention further comprises one or more additional steps of drying separately each one of the plurality of pellets obtained in each one of the coating step in order to remove the solvents and humidity; and optionally another further step of sieving the plurality of pellets if agglomération of powder into granules is observed.
In an embodiment, the drying steps are performed at a température from 20°C to 60°C; preferably from 25°C to 45°C. In a particular embodiment, the inter-coating drying steps are carried out during not less than 1 h at a température from 15°C to 45 °C, with a coating pan speed from 0 to 10 rpm and with an airflow nigner than 1 m3 / h per kg of inert nucléus. In a particular embodiment, the drying step of the external coating of the pellets is carried out during not less than 8 h and not more than 12 h at a température from 15 °C to 60 °C, preferably from 25°C to 50 °C; more particularly from 40°C to 45 °C, with coating pan speed from 0 to 10 rpm and with an airflow higher than 1 m3 / h per kg of inert nucléus. In an embodiment, the process ofthe présent invention further comprises one or more additional steps of sieving the plurality of pellets until having a sieving size from equal to or higher than 500 pm to equal to or lower than 1500 pm; particularly equal to or higher than 600 pm to equal to or lower than 1320 pm; more particularly from equal to or higher than 710 pm to equal to or lower than 1180 pm.
In an embodiment, the process is one wherein the modified release multiple unit oral dosage form exhibits a dissolution profile according to which:
from 10% to 35% by weight of doxylamine content is dissolved at 1sth in 0.1 N HCl medium (pH=1);
then, the medium is replaced by a pH = 4.5 medium (0.05 M acetate buffer) and at 4th h from an accumulated 45% to 70% by weight of doxylamine initial content is dissolved;
then, the medium is replaced by a pH = 6,8 medium (0.05 M phosphate buffer) and at Ά h at least an accumulated 80% of doxylamine initial content is dissolved;
from 10% to 35% by weight of pyridoxine content is dissolved at 1sth in 0.1 N HCl medium (pH= 1);
then, the medium is replaced by a pH = 4.5 medium (0.05 M acetate buffer) and at 4th h from an accumulated 40% to 65% by weight of pyridoxine initial content is dissolved: then, the medium is replaced by a pH = 6.8 medium (0.05 M phosphate buffer) and at 7th h at least an accumulated 80% of pyridoxine initial content is dissolved; and wherein the dissolution profile is measured using a USP type II apparatus (basket), placing the composition in 900mL of the corresponding media / buffer at 37°C ±0.5 °C and 100 rpm.
In an embodiment, the process of the présent invention wherein the modified release multiple unit oral dosage form comprises:
a first plurality of modified release pellets of doxylamine or a pharmaceutically acceptable sait thereof comprising:
- an inert nucléus;
- an inner active coating layer comprising a therapeutically effective amount of doxylarnine or a pharmaceutically acceptable sait thereof, from 7 to 11 % by weight of one or more coating agents and from 20 to 28 % by weight of one or more pore-forming agent; and optionally one or more pharmaceutically acceptable excipients;
- an intermediate enteric release coating layer comprising from 45 to 65 % by weight of one or more enteric coating agents and from 55 to 35 % by weight of one or more pore-forming agent; and
- an external modified release coating layer comprising from 8 to 14 % by weight of one or more enteric coating agents, from 38 to 46 % by weight of one or more modified release coating agents and from 42 to 52 % by weight of one or more pore-forming agent; and a second plurality of modified release pellets of pyridoxine or a pharmaceutically acceptable sait thereof comprising:
- an inert nucléus;
- an inner active coating layer comprising a therapeutically effective amount of pyridoxine or a pharmaceutically acceptable sait thereof, and from 14 to 20 % by weight of one or more coating agents: and
- an external modified release coating layer comprising from 2 to 6 % by weight of one or more enteric coating agents, from 30 to 45 % by weight of one or more modified release coating agents and from 50 to 65 % by weight of one or more pore-forming agents.
In an embodiment, the process of the invention further comprises an additional step of encapsulating the first plurality of pellets of doxylarnine or a pharmaceutically acceptable sait thereof and the second plurality of pellets of pyridoxine or a pharmaceutically acceptable sait thereof into capsules; particularly into hard capsules. The encapsulating step can be carried out by methods known in the art,
Throughout the description and claims the word comprise and variations of the word, are not intended to exclude other technical features, additives, components, or steps. Furthermore, the word “comprise” encompasses the case of “consisting of’. Additional objects, advantages and features of the invention will become apparent to those skilled in the art upon examination ofthe description or may be learned by practice ofthe invention. The following examples are provided by way of illustration, and they are not intended to be limiting of the présent invention. Furthermore, the présent invention covers ail possible combinations of particular and preferred embodiments described herein.
Examples
1. Process for manufacturinq capsules of pellets of doxylamine succinate and pyridoxine hydrochloride of the présent invention
1.1. Quantitative composition per hard capsule
The amount of each one of the ingrédients per capsule is as follows:
| Ingrédient | Quantity per capsule (mg) | Function |
| Active ingrédients | ||
| Doxylamine succinate | 10.0 | Active ingrédient |
| Pyridoxine hydrochloride | 10.0 | Active ingrédient |
| Excipients | ||
| Sugar spheres | 79.5 | Inert nucléus |
| (dewaxed) Shellac | 7.6 | Coating agent |
| Polyvinylpyrrolidone (Povidone K-30) | 0.2 | Coating agent |
| Talc | 9.5 | Pore-forming agent |
| Methacrylic acid-methyl méthacrylate copolymer (1:1) (Eudragit L) | 1.1 | Enteric coating agent |
| Silica colloïdal anhydrous (Aerosil) | 0.7 | Anticaking, gliding agent |
| Hard gélatine capsule© | 48 | Packing of dose unit |
| Capsule fill weight | 118.6 | |
| Capsule total weight | 166.6 |
(1) The gélatine capsule is made of 0.0211% of indigotine-FD&C blue 2 (E132), 0.01% of quinoline yellow (E104), 1.8% of titanium dioxide (E171) and q.s.p. 100% of gélatine.
1.2. Quantitative composition per plurality of pellets
1.2.1. Composition of the pellets of doxylamine succinate
The amount of each one of the ingrédients per a batch of about 180 Kg of the pellets of doxylamine succinate is as follows:
| Layer of the pellet | Ingrédients | function | Amount per batch (kg) |
| Core | Sugar spheres of sucrose and starch | Inert nucieus | 112.564 |
| Inner active coating layer | Doxylamine succinate | Active ingrédient | 30.200 |
| Talc | Pore-forming agent | 10.067 | |
| Silica colloïdal anhydrous (Aerosii 200 pharma) | Anti-caking agent, giiding agent | 2.013 | |
| Polyvinyl pyrrolidone 20% OVlUllVIt Ht omcutüi (Povidone K-30) | Coating agent solution | 3.020 | |
| (dewaxed) Shellac 40% solution in éthanol | Coating agent solution | 8.419 | |
| intermediate enteric release layer | Talc | Pore-forming agent | 0.641 |
| Methacrylic acid and methyl méthacrylate copolymer (1:1) (Eudragit L 10% in acetone | Enteric release coating agent mixture | 6.406 | |
| External modified release layer | Methacrylic acid and methyl méthacrylate copolymer (1:1) (Eudragit L) 10% in acetone | Enteric release coating agent mixture | 21.155 |
| (dewaxed) Shellac 40% solution in éthanol | Modified release coating agent solution | 21.156 | |
| Talc | Pore-forming agent | 9.425 | |
| Total dry weight: 180.14 |
1.2.2. Composition of the pellets of pyridoxine hydrochloride
The amount of each one of the ingrédients per a batch of about 180 Kg of the pellets of pyridoxine hydrochloride is as follows:
| Layer of the λλΙ 1 | Ingrédients | function | Amount per batch (Kg) |
| Core | Sugar spheres of sucrose and starch | Inert nucieus | 129.285 |
| pyridoxine hydrochloride | Active ingrédient | 30.600 |
| Inner active coating layer | (dewaxed) Shellac 40% solution in éthanol | Coating agent solution | 15.300 |
| External modifîed release layer | Methacrylic acid and methyl méthacrylate copolymer (1:1) (Eudragit L) 10% in acetone | Enteric release coating agent mixture | 4.896 |
| (dewaxed) Shellac 40% solution in éthanol | Modifîed release coating agent solution | 12.677 | |
| Talc | Pore-forming agent | 8.743 |
Total dry weight: 180.31
1.3. Préparation process by powder coating
1.3.1. Population of pellets of doxylamine succinate
A. Préparation of phases
Phase 1-powdered mixture for the préparation ofthe inner active coating layer: The abovementioned amount of doxylamine succinate, aerosil 200 pharma and talc disclosed above were mixed in a coating pan.
Phase 2-binding solution for the préparation of the inner active coating layer: The abovementioned amount of povidone K30 20 % in éthanol and (dewaxed) shellac 40 % in éthanol were mixed.
Phase 3-coating solution for the préparation of the external coating: The above-mentioned amount of (dewaxed) shellac 40% in éthanol and Eudragit L 10% in acetone were mixed.
B. Préparation process
-inner active coating layer
The sugar spheres were transferred into a coating pan, and then binding solution phase 2 was sprayed over the sugar spheres, kept at in rotation in the coating pan, at a spray flow rate of 100 g/min. While phase 2 was sprayed, powdered mixture Phase 1 was added (in solid form) over the sugar spheres at a solid addition rate of 370 g/min. The spraying step was performed at a rotation rate of 16 rpm, keeping the core température of the pellets between 17°C and 22°C and the airflow lower than 100 m3/h
The coated pellets thus obtained were dried during not less than 2 h at room température by keeping them rotate in the coating pan at a rate comprised between 0 and 10 rpm and with an airflow >130 m3/h to obtain the dried coated pellets with the inner active coating layer having the active ingrédient. If necessary, the dried pellets can be sieved and unwanted particle size, powders and aggregates were discarded.
-intermediate enteric release coating layer
On the coated active pellets obtained in previous step, a mixture of Eudragit L 10 % in acetone was sprayed at a spray flow rate of 100 g/min per kg of inert nucieus. While Eudragit was sprayed, talc in solid form was applied over the pellets to obtain the pellets coated with the inner active coating layer and the intermediate enteric release coating layer at a solid addition rate of 10 g,'min and at a rotation rate of 16 rpm, keeping the core température of the pellets between 17°C and 22°C and the airflow lower than 100 m3/h. The obtained coated pellets were dried during not less than 1 h at room température by keeping them rotate in the coating pan at a rate comprised between 0 and 10 rpm and with an airflow >130 m3/h.
-external modified release coating layer
Then, phase 3 was sprayed over the bi-layered coated pellets obtained in previous step at a spray flow rate of 100 g/min. While phase 3 was sprayed, talc was applied in solid form at a solid addition rate of 20 g/min and at a rotation rate of 16 rpm, keeping the core température of the pellets between 17°C and 22°C and the airflow lower than 100 m3/h. The obtained coated pellets were dried during not less than 8 h and up to 12 h at 40-45 °C by keeping them rotate in the coating pan at a rate comprised between 0 and 10 rpm and with an airflow >130 m3/h
The pellet thus obtained has the target dissolution profile. If necessary, the dried pellets can be sieved and unwanted particle size, powders and aggregates were discarded.
The modified release peïîets of doxylamine succinate thus obtained were stored in 50 kg closed double food pharmaceutical grade polyethylene bags inside closed High Density Polyethylene daims.
1.3.2. Plurality of pellets of pyridoxine hydrochloride
A. Préparation of phases
Phase 4 -coating solution for the préparation ofthe external coating: The above-mentioned amount of (dewaxed) shellac 40% in éthanol and Eudragit L 10% in acetone were mixed. B. Préparation process
-inner active coating layer
The sugar spheres were transferred into a coating pan, and then a solution of (dewaxed) shellac 40 % in éthanol was sprayed over the sugar spheres kept in rotation at a rotation speed of 16 rpms and at a spray flow rate of 100 g/min in the coating pan. While a solution of (dewaxed) shellac 40 % in éthanol was sprayed, pyridoxine hydrochloride was added in solid form over the sugar spheres at a solid addition rate of 200 g min, keeping the core température of the pellets between 17°C and 22°C and the airflow lower than 100 m3/h The coated pellets thus obtained were dried during not less than 2 h at room température by keeping them rotate in the coating pan at a rate comprised between 0 and 10 rpm and with an airflow >130 m3/h to obtain the dried coated pellets with the inner active coating layer having the active ingrédient. If necessary, the dried pellets can be sieved and unwanted particle size, powders and aggregates were discarded.
-external modified release coating layer
On the coated active pellets obtained in previous step, phase 4 was sprayed at flow rate of 100 g/min. While solution phase 4 was sprayed, talc was applied in solid form at a solid addition rate of 50 g/min and a rotation rate of 16 rpm, keeping the core température of the pellets between 17°C and 22°C and the airflow lower than 100 m3/h. The obtained coated pellets were dried during not less than 8 h and up to 12 h at 40-45 °C by keeping them rotate in the coating pan at a rate comprised between 0 and 10 rpm and with an airflow >130 m3/h.
The pellet thus obtained has the target dissolution profile. If necessary, the dried pellets can be sieved and unwanted particle size, powders and aggregates were discarded.
The modified release pellets of pyridoxine hydrochloridè thus obtained were stored in 50 kg closed double food pharmaceutical grade polyethylene bags inside closed High Density Polyethylene drums.
Capsule filling
Each Hard capsule was filled with 60 mg of the modified release pellets of doxylamine succinate and 60 mg of the modified release pellets of pyridoxine hydrochloride of the présent invention as defined above using a Bosch Zanussi E48 automatic capsule-filling machine.
2. Dissolution Test
Dissolution profile
The target dissolution profile requires that both the doxylamine succinate and the pyridoxine hydrochloride were slightly dissolved under the stomach conditions and that the major therapeutic concentration was achieved in the intestinal tract due to its rapid dissolution rate. In particular, the process for the préparation ofthe présent invention allows obtaining capsules, filled with such a modified release pellets of doxylamine succinate and modified release pellets of pyridoxine hydrochloride, which exhibît a dissolution profile according to which:
from 10% to 35% by weight of doxyiamine content is dissolved at 1sth in 0.1 N HCl medium (pH = 1);
then, the medium is replaced by a pH = 4.5 medium (0.05 M acetate buffer) and at 4th h from an accumulated 45% to 70% by weight of doxyiamine initial content is dissolved;
then, the medium is replaced by a pH = 6.8 medium (0.05 M phosphate buffer) and at 7sh h at least an accumulated 80% of doxyiamine initial content is dissolved;
from 10% to 35% by weight of pyridoxine content is dissolved at 1SÎh in 0.1 N HCl medium (pH=1);
then, the medium is replaced by a pH = 4.5 medium (0.05 M acetate buffer) and at 4th h from an accumulated 40% to 65% by weight of pyridoxine initial content is dissolved; and then, the medium is replaced by a pH = 6.8 medium (0.05 M phosphate buffer) and at 7^ h at least an accumulated 80% of pyridoxine initial content is dissolved.
wherein the dissolution profile is measured using a USP type II apparatus (basket), placing the composition in 900mL of the corresponding media / buffered 37°C ±0.5 °C and 100 rpm.
Conditions of the dissolution bath
- Paddle speed: 100 rpm
- Température of dissolution medium: 37 °C ± 0.5 °C
- Dissolution media: hydrochîoric acid 0.1 N
- Vessel volume: 900 mL
- Time: 1 hour
- Dissolution media: pH 4.5; 0.05 M acetate buffer
- Vessel volume: 900 mL
- Time: From the 1st h to the 4th hour
- Dissolution media: pH 6.8: 0,05 M phosphate buffer
- Vessel volume: 900 mL
- Time: From the 4th h to the 7th hour
Conditions of the chromatographie analysis
- Sample préparation: Take an aliquot of approximately 10 ml and filter it through 0.70 pm membrane filter, then filter it through another 0.22 pm membrane filter.
- Flux: 1 mL/min
- Column: Kromasil 100-5 C18, 150 x 4.0 mm
- Phases: methanol in water
- Injection volume: 100 pL
- Excitation wavelength: 220 nm
- Chromatographie time: 25 msn.
- Aqueous phase: Ammonium acetate buffer 0.06 M p'ri 5.0 + 0.1% sodium hexanesulfonate (PICB6)):
- Gradient:
Time (min) Methanol (%) Aqueous phase (%)
| 0 | 20 | 80 |
| 4 | 32.5 | 80 |
| 8 | 100 | 50 |
| 13 | 100 | 50 |
| 17 | 20 | 80 |
| 25 | 20 | 80 |
Results
The dissolution profite ofthe capsule ofthe présent invention which comprises pellets of 10 doxylamine succinate and pyridoxine hydrochloride
| pH | Time (hours) | Dissolved doxylamine succinate (%) | Dissolved pyridoxine hydrochloride (%) |
| 1 | 0.5 | 11.3 | 9.3 |
| 1 | 22.3 | 16.5 | |
| 4.5 | 2 | 38.7 | 33.0 |
| 3 | 47.6 | 44.0 | |
| 4 | 54.S | 52.8 | |
| 6.8 | 5 | 84.6 | 74.4 |
| a V | 93.8 | 90.2 | |
| 7 | 97.2 | 97.8 | |
| Thec | issolution profile as disclosed above show that t | he capsules of the invention hâve the |
required dissolution profite. Thus, the dissolution of both doxylamine succinate and pyridoxine hydrochloride when it is submitted to stomach conditions is. at least a 10% of 15 the total amount in 1 hour and at least a 40% of doxylamine succinate and pyridoxine hydrochloride after 4 hours is dissolved when it is submitted to duodenal conditions (pH =
4.5) and at least an 80% of doxylamine succinate and pyridoxine hydrochloride after 7 hours is dissolved when it is submitted to colon conditions.
Citation List
1. WO2013123569
2. WO2016029290
Claims (11)
- Ciaims1. A process for the préparation of a modified release multiple unit oral dosage forms comprising:a first plurality of modified release pellets of doxylamine or a pharmaceutically acceptable sait thereof comprising:- an inert nucléus;- an inner active coating layer comprising a therapeutically effective amount of doxylamine or a pharmaceutically acceptable sait thereof, one or more coating agents and one or more pore-forming agent; and optionally one or more pharmaceutically acceptable excipients;- an intermediate enteric release coating layer comprising one or more enteric coating agents and one or more pore-forming agent; and- an external modified release coating layer comprising one or more enteric coating agents, one or more modified release coating agents and one or more pore-forming agent; and a second plurality of modified release pellets of pyridoxine or a pharmaceutically acceptable sait thereof comprising:- an inert nucléus;- an inner active coating layer comprising a therapeutically effective amount of pyridoxine or a pharmaceutically acceptable sait thereof, and one or more coating agents; and- an external modified release coating layer comprising one or more enteric coating agents, one or more modified release coating agents and one or more pore-forming agents;wherein the process comprises:- preparing the first plurality of modified release pellets of doxylamine or a pharmaceutically acceptable sait thereof by coating the pellets of doxylamine or a pharmaceutically acceptable sait thereof having the inner active coating layer and the intermediate enteric coating layer by simultaneous spraying a mixture comprising from 2.0 to 7.5 % by weight of the enteric coating agents and from 15,0 to 35.0 % by weight of the modified release coating agents in a weight ratio from 5:95 to 30:70; and adding the pore-forming agents in powder form, wherein: the spray flow rate of the mixture comprising the coating agents is from 300 to 1200 mg / min per kg of inert nucléus; the solid addition rate of the poreforming agents is from 75 to 500 mg/min per Kg of inert nucléus; and the relation between the spray flow rate of the mixture comprising the coating agents and the addition rate of the pore-forming agents in solid form is from 90:10 to 60:40; and- preparing the second plurality of modified release pellets of pyridoxine or a pharmaceutically acceptable sait thereof by coating the pellets of pyridoxine or a pharmaceutically acceptable sait thereof having the inner active coating layer by simultaneous spraying a mixture comprising from 2.0 to 7.5 % by weight of the enteric coating agents and from 15.0 to 35.0 % by weight of the modified release coating agents in a weight ratio from 5:95 to 30:70; and adding the pore-forming agents in powder form, wherein: the spray flow rate of the mixture comprising the coating agents is from 300 to 1200 mg / min per kg of inert nucléus; the solid addition rate of the pore-forming agents is from 75 to 500 mg/min per Kg of inert nucléus; and the relation between the spray flow rate of the mixture comprising the coating agents and the addition rate of the pore-forming agents in solid form is from 90:10 to 60:40.
- 2. The process according to claim 1, wherein:the process comprises:- preparing the first plurality of modified release pellets of doxylamine or a pharmaceutically acceptable sait thereof as defined in claim 1, wherein the solid addition rate of the poreforming agents is from 88 to 195 mg/min per Kg of inert nucléus; and- preparing the second plurality of modified release pellets of pyridoxine or a pharmaceutically acceptable sait thereof as defined in claim 1, wherein the solid addition rate of the pore-forming agents is from 193 to 425 mg/min per Kg of inert nucléus; and/or the process comprises:- preparing the first plurality of modified release pellets of doxylamine or a pharmaceutically acceptable sait thereof as defined in claim 1, wherein the relation between the spray flow rate of the mixture comprising the coating agents and the solid addition rate of the pore- forming agents is from 90:10 to 60:40; and- preparing the second plurality of modified release pellets of pyridoxine or a between the spray flow rate of the mixture comprising the coating agents and the solid addition rate of the pore-forming agents is from 90:10 to 60:40:particularly, wherein the mixture comprises from 2.5 to 5.5% by weight of the enteric coating agents and from 18 to 30% by weight of the modified release coating agents.
- 3. Theprocessaccordingtoanyoftheclaims 1 or2,whereintheprocessfurthercomprises a previous step of coating separately:- coating the pellets of doxylamine or a pharmaceutically acceptable sait thereof having the inner active coating layer by simultaneous spraying of a mixture comprising from 5 to 15% of the enteric coating agents and adding from 5.5 to 6.0 g per kg of inert nucléus of the pore-forming agents in powder form; wherein the spray flow rate of the mixture comprising from 5 to 15% by weight of one or more enteric coating agents is from 445 to 1000 mg/min per kg of inert nucléus; the solid addition rate of the pore forming agent is from 45 to 100 mg/min per Kg of inert nucléus; and the relation between the spray flow rate of the mixture comprising the coating agents and the solid addition rate is from 87:13 to 93:7; and -coating the inert nucléus with a simultaneous spraying of a mixture comprising from 30 to 45% of one or more coating agents and adding the therapeutically effective amount of pyridoxine or a pharmaceutically acceptable sait thereof in powder form: 'wherein the spray flow rate of the mixture comprising from 30 to 45% of one or more coating agents is from 385 to 850 mg/min per Kg of inert nucléus; the solid addition rate of the powder is from 770 to 1700 mg /min per Kg of inert nucléus; and the relation between the spray flow rate of the mixture comprising the coating agents and the powdered mixture is from 25:75 to 40:60.
- 4. The process according to any of the claims 1-3, wherein the particle size of doxylarnine or a pharmaceutically acceptable sait thereof and pyridoxine or a pharmaceutically acceptable sait thereof is from 1 pm to 250 pm; and /or the pore-forming agent has a particle size from 1 pm to 250 pm.
- 5. The process according to any of the claims 1-4, wherein the process further comprises an additional step which comprises coating the inert nucïeus with a simultaneous spraying of a mixture comprising from 30 to 40% by weight one or more coating agents and adding a powdered mixture of the therapeutically effective amount of doxylarnine or a pharmaceutically acceptable sait thereof from 22 to 30% by weight of the pore-forming agents, and optionally one or more pharmaceutically acceptable excipients; wherein the spray flow rate of the mixture comprising from 30 to 40% by weight one or more coating agents is from 445 to 1000 mg/min per Kg of inert nucléus; the solid addition rate of the powdered mixture is from 1.64 to 3.62 g/min per Kg of inert nucléus; and the relation between the spray flow rate of the mixture comprising the coating agents and the solid addition rate of the powdered mixture is from 15:85 to 25:75.
- 6. The process according to any of the claims 1-5, wherein the modified release multiple unit oral dosage form comprising doxylarnine succinate and pyridoxine hydrochloride.
- 7. The process according to any ofthe claims 1-6, wherein the modified release multiple units oral dosage form is a hard capsule comprising from 5 mg to 50 mg per capsule of doxylarnine succinate and from 5 mg to 50 mg per capsule of pyridoxine hydrochloride.
- 8. The process according to any of the claims 1-7, wherein:the coating agents of the inner active coating iayer of peliets of doxylamine or a pharmaceutically acceptable sait thereof are selected from the group consisting polyvinylpyrrolidone, shellac, hypromellose, hydroxypropylcellulose, microcrystalline cellulose and a mixture thereof; or alternatively the pore-forming agent is selected from the group consisting of talc, micronized sugar, sodium or potassium chloride and a mixture thereof, and,'or the enteric coating agents is selected from the group consisting of copolymer of methacrylic acid and methyl méthacrylate, copolymer of methacrylic acid and methyl acrylate, cellulose acetate phthalate, hydroxypropyl methyl cellulose phthalate, polyvinyl acetate phthalate, sodium alginate, cellulose acetate trimellitate and a mixture thereof.
- 9. The process according to any of the daims 1-8, wherein the process further comprises an additional step of drying separately each one of the plurality of pellets obtained in each one of the coating step, wherein the drying step is performed at a température from 15 °C to 60 °C and an airflow >1 m3 / (h per kg inert nucléus) during the appropriate period of time for having less than 5000 ppm of each of the solvents used in the process.
- 10. The process according to any of the daims 1-9, wherein the modified release multiple unit oral dosage form exhibits a dissolution profile according to which:from 10% to 35% by weight of doxylamine content is dissolved at 1sth in 0.1 N HCl medium (pH= D;then, the medium is replaced by a pH = 4.5 medium (0.05 M acetate buffer) and at 4th h from an accumulated 45% to 70% by weight of doxylamine initial content is dissolved;then, the medium is replaced by a pH = 6.8 medium (0.05 M phosphate buffer) and at 7ih h at least an accumulated 80% of doxylamine initial content is dissolved;from 10% to 35% by weight of pyridoxine content is dissolved at 1sth in 0.1 N HCl medium (pH = 1);then, the medium is replaced by a pH = 4.5 medium (0.05 M acetate buffer) and at 4th h from an accumulated 40% to 65% by weight of pyridoxine initial content is dissolved;then, the medium is replaced by a pH = 6.8 medium (0.05 M phosphate buffer) and at 7thh at least an accumulated 80% of pyridoxine initial content is dissolved; and wherein the dissolution profile is measured using a USP type II apparatus (basket), placing the composition in 900mL of the corresponding media / buffered at 37°C ± 0.5 °C and 100 rpm.
- 11. The process according to any of the claims 1-10, wherein the modified release multiple unit oral dosage form comprises:a first plurality of modified release pellets of doxylamine or a pharmaceutically acceptable sait thereof comprising:- an inert nucléus;- an inner active coating layer comprising a therapeutically effective amount of doxylamine or a pharmaceutically acceptable sait thereof, from 7 to 11 % by weight of one or more coating agents and from 20 to 28 % by weight of one or more pore-forming agent; and optionally one or more pharmaceutically acceptable excipients:- an intermediate enteric release coating layer comprising from 45 to 65 % by weight of one or more enteric coating agents and from 55 to 35 % by weight of one or more pore-forming agent; and- an externai modified release coating layer comprising from 8 to 14 % by weight of one or more enteric coating agents, from 38 to 46 % by weight of one or more modified release coating agents and from 42 to 52 % by weight of one or more pore-forming agent; and a second plurality of modified release pellets of pyridoxine or a pharmaceutically acceptable sait thereof comprising:- an inert nucléus:- an inner active coating layer comprising a therapeutically effective amount of pyridoxine or a pharmaceutically acceptable sait thereof, and from 14 to 20 % by weight of one or more coating agents; and- an external modified release coating layer comprising from 2 to 6 % by weight of one or more enteric coating agents, from 30 to 45 % by weight of one or more modified release coating agents and from 50 to 65 % by weight of one or more pore-forming agents.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18382687.4 | 2018-09-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA20182A true OA20182A (en) | 2021-12-30 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4789806B2 (en) | Pantoprazole multiparticulate formulation | |
| JP6368242B2 (en) | Pharmaceutical composition comprising 40-O- (2-hydroxy) ethyl-rapamycin | |
| JP2002523443A (en) | Omeprazole preparation | |
| WO2012001705A2 (en) | Pharmaceutical compositions of (r)-lansoprazole | |
| CA2555295C (en) | Extended release coated mini-tablets of venlafaxine hydrochloride | |
| EP4125825B1 (en) | A modified release multiple unit oral dosage form of doxylamine succinate and pyridoxine hydrochloride and a process for its preparation | |
| AU2019348630B2 (en) | A process for the preparation of a modified release multiple unit oral dosage form of doxylamine succinate and pyridoxine hydrochloride | |
| JP2008524317A (en) | Enteric coated azithromycin multiparticulates | |
| OA20182A (en) | A process for the preparation of a modified release multiple unit oral dosage form of doxylamine succinate and pyridoxine hydrochloride. | |
| US20070092568A1 (en) | Galantamine compositions | |
| HK40052488A (en) | A process for the preparation of a modified release multiple unit oral dosage form of doxylamine succinate and pyridoxine hydrochloride | |
| SI21637A (en) | Pharmaceutical form with controlled release | |
| HK40052488B (en) | A process for the preparation of a modified release multiple unit oral dosage form of doxylamine succinate and pyridoxine hydrochloride | |
| JP2022535748A (en) | Modified Release Formulations and Methods of Treatment of Pyrimidinylaminopyrazole Compounds | |
| EA044924B1 (en) | METHOD FOR OBTAINING MULTI-ELEMENT ORAL DOSAGE FORM WITH MODIFIED RELEASE OF DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE | |
| WO2008062426A2 (en) | Formulation of benzazepine derivatives | |
| HK40085497A (en) | A modified release multiple unit oral dosage form of doxylamine succinate and pyridoxine hydrochloride and a process for its preparation | |
| HK40085497B (en) | A modified release multiple unit oral dosage form of doxylamine succinate and pyridoxine hydrochloride and a process for its preparation | |
| OA21340A (en) | A modified release multiple unit oral dosage form of doxylamine succinate and pyridoxine hydrochloride and a process for its preparation. | |
| HUP0600064A2 (en) | Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl) quinazoline | |
| WO2010138064A1 (en) | Aqueous film coating composition | |
| EP1895985A1 (en) | Morphine sulphate formulations | |
| JP2008115083A (en) | Coated granule containing tramadol hydrochloride |